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https://doi.org/10.1016/j.celrep.2021.109455SUMMARYIn glioblastoma (GBM), the most frequent and lethal brain tumor, therapies suppressing recurrently altered
signaling pathways failed to extend survival. However, in patient subsets, specific genetic lesions can confer
sensitivity to targeted agents. By exploiting an integrated model based on patient-derived stem-like cells,
faithfully recapitulating the original GBMs in vitro and in vivo, here, we identify a human GBM subset (9%
of all GBMs) characterized by ERBB3 overexpression and nuclear accumulation. ERBB3 overexpression is
driven by inheritable promoter methylation or post-transcriptional silencing of the oncosuppressor miR-
205 and sustains the malignant phenotype. Overexpressed ERBB3 behaves as a specific signaling platform
for fibroblast growth factor receptor (FGFR), driving PI3K/AKT/mTOR pathway hyperactivation, and overall
metabolic upregulation. As a result, ERBB3 inhibition by specific antibodies is lethal for GBM stem-like cells
and xenotransplants. These findings highlight a subset of patients eligible for ERBB3-targeted therapy.INTRODUCTION
Glioblastoma (GBM; WHO grade IV glioma) therapy is still based
on a standard protocol established in 2005 that encompasses
surgery, which is often suboptimal for the infiltrative nature of
the tumor, followed by radiotherapy and chemotherapy with te-
mozolomide (Hegi et al., 2005). GBM molecular characterization
by transcriptional subtyping and identification of recurrent sub-
type-specific genetic alterations contributed to refining its diag-
nostic classification, but these methods have not helped to
discern prognostic subgroups or to instruct new therapeutic pro-
tocols (Reifenberger et al., 2017). Intratumor genetic heteroge-
neity, including mosaic amplification of the main druggable tar-
gets such as receptor tyrosine kinases (RTKs), which overall
occurs in more than 60% of patients (Brennan et al., 2013; Snu-This is an open access article under the CC BY-Nderl et al., 2011), sets the premises for resistance to therapeutic
agents hitting a single target, likely ending up in positive selection
of coexisting tumor subclones that rely on alternative genetic al-
terations. On the other hand, targeting a common signaling hub
such as phosphatidylinositol 3-kinase (PI3K), presumptively hy-
peractivated by RTK alterations and/or PTEN biallelic loss, failed
to provide a benefit for the high risk of generalized toxicity (Le
Rhun et al., 2019).
Nevertheless, the principle of targeting genetic alterations has
been beneficial in an ample spectrum of tumors, from lung can-
cers harboring alterations, such as ALK translocations,
epidermal growth factor receptor (EGFR) mutations, or MET
exon 14 skipping (Yang et al., 2020), to a small GBM-subsethar-
boring BRAF mutations (Reifenberger et al., 2017). In such
cases, the targeted alterations were likely selected during tumorCell Reports 36, 109455, July 27, 2021 ª 2021 The Authors. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(legend on next page)






OPEN ACCESSDarwinian evolution for providing benefits so essential to confer
a dependence known as ‘‘oncogene addiction’’ (Sharma and
Settleman, 2007).
To find out ‘‘addictive’’ GBM targets, it seems important to un-
earth the molecular mechanisms that are fixed by genetic alter-
ations and challenge their requirement for tumor cell viability. To
this aim, we exploited GBM neurospheres (NSs), long-term
propagating cultures enriched in stem-like cells (GSCs), which
faithfully retain the genomic landscape and the transcriptomic
features of the original tumors and reliably recapitulate the tumor
properties upon transplantation in the mouse (De Bacco et al.,
2012, 2016; Li et al., 2008). By perusing a panel of 84 NSs in
search for uncommon RTK alterations, we identified a subset
that, by transcriptional profiling, was characterized by high
ERBB3 gene expression and corresponded to patients with
dismal prognosis. In this integrated model, we identified miR-
205 epigenetic inactivation (i.e., transcriptional repression by
promoter methylation or post-translational silencing) as a mech-
anism that sustains ERBB3 overexpression and is inheritable
across tumor cell generations.Moreover, we found out that over-
expressed ERBB3, an EGFR family member (Yarden and Pines,
2012), heterodimerizes with FGFR and orchestrates a chain of
intracellular responses leading from FGF stimulation to
enhanced energetic and biosynthetic metabolism. This feature
is crucial to the malignant phenotype, conferring both a selective
advantage and a liability so that, as we show, ERBB3 inhibition is
lethal for GBM cells in vitro and in vivo.
RESULTS
ERBB3 overexpression defines a subset of proneural
GBM with oligodendroglial features and dismal
prognosis
In GBM, RTK overexpression, which is often sustained by gene
amplification, significantly contributes to tumorigenesis and pro-
vides potential therapeutic targets (Reifenberger et al., 2017). To
identify GBM subgroups characterized by altered expression of
specific RTKs, we exploited a panel of 84 NSs (84 NS-panel),
derived from as many primary GBMs. ERBB3 expression, previ-
ously associated with the proneural GBM subtype (Verhaak
et al., 2010), was found remarkably high (log2ratio > 2.5) in aFigure 1. ERBB3 overexpression defines a subset of proneural GBM w
(A) Heatmap showing spontaneous clustering of the 84 NS-panel according to m
(B) ERBB3 mRNA expression (log2ratio [L2R], microarray) in NSs classified in the
preferentially falling in the proneural subtype (one-way ANOVA, p = 0.03). Mean
(C) ERBB3mRNA expression (L2R,microarray) in NSs classified in the 3 subtypes
II (one-way ANOVA, p < 0.001). Mean ± SEM.
(D) Caleydo view of correspondence between the 84-NS panel classification acco
high NS.
(E) mRNA expression of oligodendrocyte, astrocyte, and neuronmarkers (accordi
low/neg NS (log fold change).
(F) Survival curve of patients (all untreated) that originated the 84-NS panel, su
matched with NSs displaying ERBB3 L2R > 2.5; ERBB3-low/neg, all other patien
(G) Survival curve in the TCGA cohort of untreated primary proneural patients w
patients with ERBB3 mRNA levels falling in the upper quartile; ERBB3-low/neg,
(H) ERBB3 expression in representative patients (top panels, immunohistochemi
GBMs obtained by NS orthotopic transplant (bottom panels, IHC). Insets, arrows
See also Figures S1 and S2 and Tables S1, S2, and S3.small subgroup of 7 NSs (8.4%, hereafter indicated as ERBB3-
high NS), characterized by a globally very low expression of
themain GBM-associated RTKs (EGFR, ERBB2, platelet derived
growth factor receptor alpha [PDGFRA] and MET) (Figure 1A).
These NSs were derived from tumors that displayed high
ERBB3 expression as well (Figure S1A). An analysis of the The
Cancer Genome Atlas (TCGA) GBM cohort (n = 528) identified
a tumor subgroup (9.3%), classified as proneural, which dis-
played similar properties, i.e. high ERBB3 expression associated
with low levels of the other RTKs except PDGFRA (Figure S1B).
According to the Verhaak’s signature (Wang et al., 2017), all
NSs could be assigned either to a classical (32/84), proneural
(30/84), or mesenchymal (22/84) subtype (Figure S1C; Table
S1). Six out of 7 ERBB3-high NS were classified as proneural,
and 1 as mesenchymal (Figure 1B). Moreover, we applied to
the NS panel a new type I-type II stratification method, based
on a signature including ERBB3 as a prominent type II marker
(Wang et al., 2020). As result, 31/84 NSs were classified as
type I, 17/84 as type II, and 36/84 remained defined as ‘‘non-
type I&II’’ (Figure S1D; Table S1;Wang et al., 2020). Interestingly,
7/7 ERBB3-high NS were included in the type II subgroup (Fig-
ure 1C). A comparison between the Verhaak’s and the type I-
type II assignments showed that type I mostly includes classical
NSs, while type II comprises, beside proneural ERBB3-high NS,
9/22 mesenchymal NSs. Finally, the non-type I&II group includes
similar percentages of proneural NSs expressing low ERBB3
levels (15/36), mesenchymal NSs (11/36), and classical NSs
(10/36) (Figure 1D). NS assignments to type I and II, as well as
to the Verhaak’s subtypes, reflected ratios reported in the
TCGA GBM cohort (Wang et al., 2017, 2020), attesting that the
84 NS-panel reliably reflects the distribution of gene expression
profiles in the patient population affected by GBM.
Consistent with assignment to the proneural/type II subsets,
ERBB3-high NS displayed a specific and significant enrichment
in an oligodendroglial gene expression signature (Figures 1E and
S1E; Cahoy et al., 2008), reflecting a likely origin from an oligo-
dendroglial progenitor (OPCs) (Wang et al., 2020). Moreover, in
both the 84 NS-panel and TCGA GBM cohort, ERBB3 expres-
sion levels correlated with those of SRY-box transcription factor
10 (SOX10), a prominent ERBB3 transcriptional regulator (Pra-
sad et al., 2011), and inversely correlated with those of theith oligodendroglial features and dismal prognosis
RNA levels of the indicated genes (microarray). Red dots, ERBB3-high NS.
3 GBM subtypes according to Wang et al. (2017). Red dots, ERBB3-high NS,
± SEM.
identified byWang et al. (2020). Red dots, ERBB3-high NS, all classified as type
rding toWang et al. (2017) (left) andWang et al. (2020) (right). Red lines, ERBB3-
ng to Cahoy et al., 2008) significantly modulated in ERBB3-high versus ERBB3-
bdivided according to ERBB3 levels in matched NSs. ERBB3-high, patients
ts (NSs with ERBB3 L2R % 2.5).
ith GBM (n = 140), subdivided according to ERBB3 expression. ERBB3-high,
all other patients.
stry [IHC]) and matched NSs (middle panels, flow cytometry) and experimental
, ERBB3 nuclear localization. Scale bar, 100 mm.
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OPEN ACCESSEGFR coexpressed SOX9 (Figures S1F and S1G), as previously
reported (Wang et al., 2020).
Concerning genetic alterations, ERBB3-high NS displayed no
statistically significant preferential association with any recurrent
GBM gene mutation or copy number variation or with ERBB3
amplification (Figures S1H and S1I). However, we could observe
that ERBB3 overexpression tended (1) to co-occur with PDGFR
andCDK4amplification orwithTP53mutation; and (2) tobemutu-
ally exclusive with EGFR amplification andCDKN2A loss (Figures
S1HandS1J). The sameassociationswere statistically significant
in ERBB3-high GBMs from the TCGA cohort (Figure S1K).
Interestingly, unlike overexpression of other RTKs, ERBB3
overexpression emerged as a strongly negative prognostic fac-
tor for patients with GBM. This prognostic correlation was
observed either in the patient cohort matched to the 84NS-panel
or in the TCGA cohort of patients with GBM (proneural sub-
group), in which the overall survival of ERBB3-overexpressing
cases was significantly reduced (Figures 1F and 1G; Table S2).
Consistently, experimental tumors generated by orthotopic
transplantation of proneural ERBB3-high NS were significantly
more aggressive than those formed by proneural NSs express-
ing normal ERBB3 levels, as shown by tumor take and prolifera-
tive index (Figures S1L and S1M).
ERBB3 overexpression is inheritable and sustained by
epigenetic inactivation of the oncosuppressor miR-205
To establish an adequate model for investigating causes and
consequences of ERBB3 overexpression, we further classified
NSs based on ERBB3 mRNA levels. Among ERBB3-positive
NSs, we discriminated the subgroup of 7 ERBB3-high NS from
those that expressed lower but above-the-average ERBB3
levels (ERBB3-low NS, 0 % log2ratio [L2R] % 2.5, n = 29/84).
The remaining were classified as ERBB3-neg NS (L2R < 0, n =
48/84) (Figure S2A; Table S1). In the following experiments,
BT308, BT209, BT314, and BT205 NSs were used as represen-
tatives of ERBB3-high; BT373 and BT302 as ERBB3-low; and
BT463 and BT287 as ERBB3-neg (Figure S2B).
The ERBB3 protein levels in ERBB3-high NSwere comparable
to those observed in reference cell lines overexpressing ERBB3,Figure 2. ERBB3 overexpression is sustained by inactivation of the on
(A) FISH analysis of ERBB3 in 5 representative ERBB3-high NS (red dots, ERBB
number of ERBB3 gene copies evaluated in 100 nuclei. Scale bar, 12.5 mm.
(B) miR-205 and ERBB3 mRNA expression (qPCR) and ERBB3 protein levels (we
coefficient between miR-205 and ERBB3 mRNA: R = 0.93, p = 0.0002). Mean
(C and D) miR-205 and ERBB3 expression (qPCR) in parental GBMs (C) that origin
transplantation of ERBB3-high or -low/neg NS (Pearson correlation coefficient be
experimental GBMs, R = 0.72, p = 0.06). Mean ± SEM, n = 3.
(E) miR-205 expression in GBMs from the TCGA cohort subdivided according to E
in the upper quartile; ERBB3-low/neg: all other patients; *p < 0.001, one-way AN
(F) miR-205 and ERBB3 mRNA expression (qPCR) in ERBB3-low/neg NS (BT463
Mean ± SEM, n = 3.
(G) Western blot showing total ERBB3 protein in BT373 and BT463 transfected a
(H) ERBB3 protein expression in ERBB3-high NS (BT308 and BT209) transduced
GAPDH, loading control.
(I) miR-205 promoter methylation ratio in ERBB3-high and -low/neg NS. ERBB
ANOVA, p < 0.0001). Mean ± SEM, n = 6.
(J and K) miR-205 expression (qPCR) in ERBB3-high NS (BT209) treated with the d
after treatment (J) and ERBB3 protein in the same NS 72 h after treatment (K). a
See also Figure S3.such as MCF7 (Figures S2C and S2D). Interestingly, by analysis
of fractionated nuclear/cytoplasmic extracts and immunofluo-
rescence, we observed that in ERBB3-high NS, ERBB3 localized
also in the nucleus (Figures S2B and S2E). ERBB3 nuclear local-
ization was previously described, but it has a still poorly under-
stood functional significance (Reif et al., 2016).
Remarkably, ERBB3 protein levels remained stable in
matched parental GBMs, NSs, and experimental tumors ob-
tained by NS orthotopic transplant. In ERBB3-high cases, the
ERBB3 protein was homogeneously overexpressed and local-
ized in the nucleus within both parental and experimental tumor
tissues and in NS cells as well (Figure 1H). ERBB3 overexpres-
sion was faithfully passed on throughout multiple cell genera-
tions, as shown by NS single-cell subcloning (Figures S2F and
S2G), and it was not downregulated after NS culture in pro-differ-
entiating conditions, unlike the expression of other genetically
unaltered RTKs such as MET (Figure S2H; De Bacco et al.,
2012). This evidence suggested that ERBB3 overexpression is
fixed by inheritable genetic mechanisms.
By investigating such mechanisms, we ruled out alterations of
the ERBB3 gene, as (1) amplifications or translocations were un-
equivocally excluded by fluorescence in situ hybridization (FISH)
(Figure 2A) in addition to qPCR (Figure S1I), and (2) mutations
known to affect protein stability (Jaiswal et al., 2013) were absent
(Figure S1H).
Considering the known mechanisms of ERBB3 post-transla-
tional control (Figure S3A) (Campbell et al., 2010), we excluded
altered ERBB3 targeting to degradation, for lack of anti-correla-
tion between ERBB3 and NEDD4 or NRDP1 ubiquitin ligase
expression levels (Figure S3B).
We thus focused onmiR-205, which is known as amajor regu-
lator of ERBB3 translation (Iorio et al., 2009; Campbell et al.,
2010). We observed a strong anti-correlation between ERBB3
and miR-205 expression in NSs and parental and experimental
tumors from our cohort and in the TCGA GBM cohort as well
(Figures 2B–2E). The impact of miR-205 on ERBB3 protein trans-
lation was confirmed in NSs by complementary approaches
such as (1) transduction of ERBB3-low/neg NS (BT463 and
BT373) with an antagomiR-205, which upregulated ERBB3cosuppressor miR-205
3 probe; green dots, chromosome 12 centromeric probe [CEN12]). n, average
stern blot) in representative NSs. calnexin, loading control (Pearson correlation
± SEM, n = 3.
ated ERBB3-high or -low/neg NS and in experimental GBMs (D) generated by
tween miR-205 and ERBB3 expression: parental GBMs, R = 0.93, p = 0.002;
RBB3 expression levels (ERBB3-high: patients with ERBB3mRNA levels falling
OVA). Mean ± SEM, n = 339.
and BT373) transfected with antagomiR-205. mock, mock-transfected cells.
s in (F). calnexin, loading control.
with miR-205. The known miR-205 target BCL2 was shown as positive control.
3-high NS display higher methylation ratio versus ERBB3-low/neg (two-way
emethylating agent 50Aza-2-deoxycytidine (50 AZA) at the indicated time points
ctin, loading control; mock, PBS-treated cells. Mean ± SEM, n = 3.
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OPEN ACCESSexpression (Figures 2F and 2G); and (2) transduction of ERBB3-
high NS (BT308 and BT209) with miR-205 (Figure S3C), which
completely abolished ERBB3 protein expression (Figure 2H).
Altogether, these data indicate that ERBB3 overexpression is
likely due to the loss ofmiR-205 expression, and the latter should
occur through inheritable genetic or epigenetic mechanisms.
Having excluded miR-205 genetic mutation by Sanger
sequencing or loss by qPCR and FISH, we investigated whether
miR-205 silencing could result from promoter hypermethylation,
a frequently reported mechanism of miR-205 inactivation (Qin
et al., 2013). We found that, indeed, the miR-205 promoter was
hypermethylated in the majority of ERBB3-high NS, but not in
ERBB3-low/neg NS (Figure 2I); accordingly, NS treatment with
the de-methylating agent 50-Aza-20-deoxycytidine concomi-
tantly increased miR-205 and decreased ERBB3 expression
(Figures 2J and 2K). As a notable exception, ERBB3-high
BT308 NS lackedmiR-205 expression (Figure 2B) in the absence
of promoter methylation (Figure 2I). In this case, we could corre-
late miR-205 silencing with overexpression of lnc-RNA SNHG5,
which acts as a miR-205 sponge (Li et al., 2019), and was highly
expressed in BT308 NS, as well as in matched parental and
experimental GBMs (Figures S3D–S3F).
We also investigated whether other microRNAs (miRNAs)
could be involved in ERBB3 targeting. By in silico analysis of
ERBB3 30 UTR seed binding regions, we identified a list of miR-
NAs displaying a complementarity score similar to miR-205 (Fig-
ure S3G), which, however, did not display any anti-correlation
with ERBB3 expression either in NSs or in the whole TCGA
GBM cohort (Figures S3H and S3I).
We can conclude that, beside the known transcriptional acti-
vator SOX10, miR-205 is essential for controlling ERBB3 expres-
sion in GBM. Notably, the loss of miR-205 expression occurs
through inheritable silencing mechanisms such as promoter hy-
permethylation or overexpression of the lnc-RNA SNHG5
(Figure S3J).
ERBB3 is overexpressed in the absence of other EGFR
family members
ERBB3 is a member of the EGFR family devoid of intrinsic tyro-
sine kinase activity. ERBB3 signaling activation requires phos-
phorylation by a kinase-competent dimerization partner, namely
another EGFR family member (Yarden and Pines, 2012). Such
heterodimerization is usually induced either by the ERBB3 ligand
Neuregulin 1 (NRG1) or by EGF-like ligands that bind EGFR
(Yarden and Pines, 2012). However, transcriptomic analysis of
the 84 NS-panel and TCGA GBM cohort showed that ERBB3
expression is mutually exclusive with EGFR amplification (Fig-
ures S1J and S1K) or expression (Figures S4A and S4B), which
are both known to be mostly associated with the classical sub-
type (Verhaak et al., 2010). Concerning expression of the other
EGFR family members, ERBB2 was anti-correlated with
ERBB3 in the TCGA GBM cohort and only weakly associated
(R = 0.047, p = 0.67) with ERBB3 in the 84 NS-panel; ERBB4
was instead significantly coexpressed with ERBB3 in the
TCGA cohort, but it was not expressed in NSs, which is consis-
tent with preferential expression of this RTK in differentiated neu-
ral and glial cells (Figures S4A and S4B) (Duhem-Tonnelle et al.,
2010). By western blot and flow cytometry, we confirmed that in6 Cell Reports 36, 109455, July 27, 2021ERBB3-high NS, the ERBB3 conventional partners EGFR,
ERBB2, or ERBB4 were neither coexpressed nor coprecipitated
with ERBB3 in the presence of the ligands EGF or NRG1 (Figures
3A–3C and S4C). The lack of EGFR and ERBB2 protein expres-
sion was confirmed in ERBB3-high parental and experimental
GBMs (Figure 3D), as well as in ERBB3-high TCGA GBM tissues
assessed by The Human Protein Atlas (Figures S4D and S4E).
Consistently, in ERBB3-high NS (kept in the absence of exoge-
nous growth factors for 48 h), NRG1 stimulation failed to induce
phosphorylation of multiple ERBB3 tyrosines and activation of
downstream transducers (mitogen-activated protein [MAP] ki-
nase and AKT), which were instead observed in spheres from
colorectal cancers coexpressing EGFR and ERBB3 and as-
sessed under the same conditions (Figure 3E; Luraghi et al.,
2018), and in representative conventional cell lines (Figure S4F).
In ERBB3-high NS, the lack of ERBB3 activation by NRG1 was
mirrored by a lack of proliferative response to NRG1 (Fig-
ure S4G); no biochemical or biological response to EGF was
observed as well (Figures S4F–S4H). Overall, these experiments
indicated that, in NSs as well as in GBMs, ERBB3 is overex-
pressed in the absence of other EGFR family members. More-
over, in NSs, ERBB3 is insensitive to its conventional ligand
NRG1 or to the EGFR ligand EGF.
Overexpressed ERBB3 is activated by bFGF through
FGFR3
The above experiments implied that proliferation of ERBB3-high
NS, which were selected and long-term propagated in a stan-
dard stem-cell medium (i.e. containing EGF and bFGF as the
sole growth factors), relied specifically on bFGF. Indeed,
ERBB3-high NS significantly responded to bFGF (Figure 3F),
without additive effects by EGF or NRG1 (Figure S4G). The com-
plete dependence of ERBB3-high NS proliferation on bFGF was
further confirmed by treatment of NSs cultured in the standard
medium with the pan-FGFR inhibitor BGJ398 (Figure S5A).
On these premises, we investigated whether, in ERBB3-high
NS, bFGF stimulation could activate ERBB3 signaling. We
indeed showed that bFGF, added as the sole growth factor,
induced not only FGFR activation (as shown by phosphorylation
of its specific fibroblast receptor substrate 2 [FRS2]) but also
ERBB3 phosphorylation, which was followed by MAPK and
AKT activation (Figures 3G and S5B), and prevented by FGFR in-
hibition with BGJ398 (Figure S5C). To investigate whether the
downstream signaling response elicited by bFGF depended on
ERBB3, we treated ERBB3-high NS with the specific ERBB3
inhibitory antibody seribantumab (also known and hereafter indi-
cated as MM121), which is capable of inducing ERBB3 pro-
longed downregulation from the cell surface and degradation
(Figures S5D and S5E), as previously described (Schoeberl
et al., 2017). In ERBB3-high BT308, MM121 quenched down-
stream signaling sustained by bFGF in the standard medium
(Figure 3H) and abolished the proliferative response to bFGF
(Figure 3I). The same inhibition was obtained by targeting
ERBB3 with a specific small hairpin RNA (shRNA) (Figure 3I).
We thus investigated whether ERBB3 could be a direct FGFR
dimerization partner and phosphorylation substrate. Among the
4 FGFR family members, we focused on FGFR3 based on the
following evidence: (1) in the 84-NS panel, only FGFR3 (and
(legend on next page)






OPEN ACCESSFGFR4) mRNA levels positively correlated with those of ERBB3
(Figure S5F); (2) in ERBB3-high NS, FGFR3 (and FGFR4) levels
were significantly higher than FGFR1 and FGFR2 mRNA levels;
conversely, all FGFRs were poorly expressed in ERBB3-low/
neg NS (Figure S5G); and (3) only FGFR3 was consistently ex-
pressed at high protein levels in representative ERBB3-high
NS (Figures S5H and S5I). The FGFR3 critical role in mediating
the bFGF signal in ERBB3-high NS was confirmed by FGFR3
expression silencing through shRNA, which fully abolished the
proliferative response to bFGF (Figure S5J). Colocalization be-
tween ERBB3 and FGFR3 was shown in both ERBB3-high NS
and experimental GBMs by immunofluorescence (Figure 3J),
and in NS by flow-cytometric analysis (Figure 3K) and single-
cell imaging (Figure 3L and S5K). A physical interaction between
ERBB3 and FGFR3 was indicated by proximity-ligation assays
(Figure 3M and S5L) and by ERBB3-FGFR3 coprecipitation in
ERBB3-high NS (Figure 3N).
Moreover, we showed that forced ERBB3 overexpression
could enable ERBB3-low/neg NS to respond to bFGF. Indeed,
ERBB3-neg/low NS, although expressing FGFR family members
(Figures 3N and S5M), were poorly sensitive to bFGF (Figure 3F)
and mostly relied on EGF for their proliferation (Figure S5N). The
proliferative response of ERBB3-neg BT463 transduced with
ERBB3 was similar to that of ERBB3-high NS and fully counter-
acted by MM121 (Figure 3O).
Finally, we investigated whether overexpressed ERBB3 could
be activated by other RTKs, including KIT and NTRK2, whichFigure 3. ERBB3 is overexpressed in the absence of the other EGFR fa
(A) Western blot showing expression of ERBB3 and the other EGFR family membe
MCF7 (antibody positive control).
(B) Flow cytometry showing lack of ERBB3 coexpression with EGFR, ERBB2, or
(C) Immunoprecipitation (IP) with antibodies against EGFR, ERBB2, and ERBB3 in
by western blot with anti-ERBB3, -EGFR, or -ERBB2 showing lack of coexpress
(D) Representative IHC staining of ERBB3, EGFR, and ERBB2 in representative ER
Scale bar, 100 mm.
(E) Western blot showing lack of ERBB3 phosphorylation on Tyr1289, Tyr1197, a
NRG1 in representative ERBB3-high (BT308) and -low (BT373) NSs. Activation of d
active owing to PTEN loss). A colosphere (colorectal cancer stem cell culture, M
(F) Cell viability assay in ERBB3-low/neg (n = 7) and ERBB3-high-NS (n = 5), after
ANOVA). Mean ± SEM.
(G) Western blot showing phosphorylation (p) of ERBB3 on Tyr1289, AKT, and MA
treated with bFGF. Phosphorylation of fibroblast receptor substrate 2 (FRS2) was
loading control. The same vinculin immunoblot is shown in Figure S7A as part of
(H) Western blot showing inhibition of ERBB3, MAPK, and AKT phosphorylation (p
NS (BT308) kept in standard medium (EGF + bFGF). mock, PBS-treated cells; vin
part of the same experiment.
(I) Cell viability of ERBB3-high BT308, kept in the absence of any growth factor for 4
NSswere either treated withMM121 or transduced with a specific ERBB3 shRNA
6.
(J) Immunofluorescence showing ERBB3 and FGFR3 colocalization in representa
staining; inset, higher magnification. Scale bar, 25 mm.
(K) Flow cytometry showing ERBB3 coexpression with FGFR3 in representative
(L) Colocalization of ERBB3 and FGFR3 measured by Amnis ImageStream in s
fluorescent antibody signals are shown. BF, bright field.
(M) Proximity ligation assay (PLA) showing ERBB3-FGFR3 interaction in represe
(N) IP with antibodies against ERBB3 or FGFR3 in representative ERBB3-high (B
anti-ERBB3 or -FGFR3 showing coprecipitation in ERBB3-high NS.
(O) Cell viability in representative ERBB3-neg NS transduced with ERBB3 (BT463
and treated with bFGF, with or without MM121. ERBB3 protein in transduced BT
versus BT463_ctrl). Mean ± SEM, n = 6.
See also Figures S4, S5, S6, and S11 (related to STAR Methods).
8 Cell Reports 36, 109455, July 27, 2021were highly expressed in ERBB3-high NS and TCGA GBMs,
andMET and PDGFR, expressed at lower levels, but well-known
to heterodimerize with ERBB3 (Figures S6A–S6C; Engelman
et al., 2007; Song et al., 2018). However, the involvement of
the above receptors was ruled out as their respective ligands
failed to induce ERBB3 phosphorylation or receptor coprecipita-
tion (Figure S6D).
Altogether, these data indicate that overexpressed ERBB3 is
specifically activated by bFGF through heterodimerization with
FGFR3 and can sensitize NSs to bFGF.
In ERBB3-overexpressing NSs, bFGF sustains the PI3K/
AKT/mTOR pathway and metabolic hyperactivation
By harboring six consensus sequences for binding p85, the reg-
ulatory PI3K subunit (Schulze et al., 2005), ERBB3 is a powerful
activator of the PI3K/AKT/mTOR pathway (Goncalves et al.,
2018; Saxton and Sabatini, 2017). This pathway is well known
for coupling growth factor signaling with anabolic metabolism
required for biomass accumulation and cell duplication (Saxton
and Sabatini, 2017). Hyperactivation of this pathway is essential
to cancer proliferation and can provide a target for therapeutic
intervention (Bi et al., 2020). As depicted in Figure 4A, down-
stream the mTOR kinase complex 1 (mTORC1) the pathway
splits into two main branches, namely, one mainly responsible
for protein and fatty acid biosynthesis and the other for upregu-
lation of glycolytic and/or oxidative metabolism. In particular, (1)
S6 kinase (S6K) activates S6, a master regulator of proteinmily members and is activated by bFGF through FGFR3
rs (EGFR, ERBB2, and ERBB4) in representative NSs and breast cancer cell line
ERBB4 in a representative ERBB3-high NS (BT209).
representative ERBB3-high (BT209 and BT308) and -neg NS (BT463), followed
ion.
BB3-high parental (top panel) and experimental (bottom panel) BT308 GBMs.
nd Tyr1222 at the indicated time points after treatment with the ERBB3 ligand
ownstream transducers AKT andMAPK is also shown (in BT308 AKT is basally
049) sensitive to NRG1 is used as positive control. actin, loading control.
4 days in the presence of bFGF as the sole growth factor (*p < 0.001, one-way
PK in ERBB3-high BT209 kept in the absence of any growth factor for 48 h and
shown as surrogate marker of FGFR activation. ctrl: PBS-treated cells; vinculin,
the same experiment.
) at different time points after treatment with or without MM121 of ERBB3-high
culin, loading control. The same vinculin immunoblot is shown in Figure 5A as
8 h and treated with bFGF or control medium (no growth factor [GF]) for 2 days.
(shERBB3). mock, PBS-treated cells (*p < 0.001, paired t test). Mean ±SEM, n =
tive ERBB3-high NS (BT308) and matched experimental GBM. DAPI, nuclear
ERBB3-high NS (BT308 and BT209).
ingle cells from representative ERBB3-high NS (BT308). Single and merged
ntative ERBB3-high NS (BT308). Scale bar, 75 mm.
T209, BT308, and BT314) and ERBB3-neg NS (BT463), and western blot with
_ERBB3) or not (BT463_ctrl), kept in the absence of any growth factor for 48 h
463 is shown. vinculin, loading control (*p < 0.001, paired t test BT463_ERBB3
(legend on next page)






OPEN ACCESSsynthesis, and sterol regulatory element binding protein 1/2
(SREBP1/2), transcription factors driving expression of de novo
fatty acid biosynthesis and pentose phosphate pathway genes
(D€uvel et al., 2010); and (2) 4E-BP1 releases elongation factor
eIF4E; this, in turn, promotes accumulation of Hypoxia Inducible
Factor-1a (HIF-1a), which upregulates transcription of glucose
uptake and glycolysis genes, including Glucose Transporter 1
(GLUT1) and Lactate Dehydrogenase B (LDHB) (D€uvel et al.,
2010); moreover, eIF4E promotes accumulation of transcription
factor A mitochondrial (TFAM), required for mitochondrial
expression of oxidative phosphorylation (OXPHOS) genes (Mor-
ita et al., 2013). In NSs, we could specifically associate activation
of the global PI3K/AKT/mTOR pathway with ERBB3 overexpres-
sion and bFGF stimulation. Indeed, in ERBB3-high NS treated
with bFGF, but not in ERBB3-neg, we observed (1) activating
phosphorylation of key signal transducers such as mTOR and
its regulator RAPTOR, S6, and 4E-BP1 (Figures 4B and S7A),
and (2) upregulation of target genes, including SREBF2 (encod-
ing SREBP2), HIF1-a, and TFAM (Figures 4C and S7B). Accord-
ingly, a statistically significant enrichment of the overall ‘‘de novo
fatty acid biosynthesis’’ and ‘‘glycolysis’’ gene sets were
observed in the transcriptome of the ERBB3-high NS panel
versus all the remaining NSs kept in standard medium, namely,
in the presence of bFGF and EGF (Figure 4D). In particular,
ERBB3 expression levels directly correlated with those of
LDHB either in NSs (Figure 4E) or in the experimental tumors
(Figure 4F) or in the TCGA GBM cohort (Figure S7C).
Accordingly, during culture in standard medium, release of the
LDHB product lactate was on average more than double in
ERBB3-high compared with ERBB3-low/neg NS, and consis-
tently, the culture medium was acidified (pH 6.8 versus 7.2) (Fig-
ures 4G and 4H). As a result, genes associated with low pH were
overall induced in ERBB3-high versus all the remaining cases in
both the 84 NS-panel and TCGA GBM cohort (Figures S7D and
S7E). Overall, representative ERBB3-high NS displayed
increased glycolytic as well as mitochondrial metabolism and aFigure 4. In ERBB3-overexpressing NSs, bFGF sustains the PI3K/AKT/
(A) Schematic representation of ERBB3/PI3K/AKT/mTOR pathway and cell meta
(B) Western blot showing phosphorylation (p) of mTOR pathway effectors in ERBB
for 48 h and treated with bFGF for the indicated time-points. ctrl, PBS-treated c
ure S5B as part of the same experiment.
(C) Expression of mTOR target genes SREBF2, HIF1A, and TFAM in ERBB3-high (B
48 h and treated with bFGF for 24 h. Mean ± SEM, n = 3.
(D) Gene set enrichment analysis of ERBB3-high versus ERBB3-low/neg NS perfo
gene sets are significantly enriched in ERBB3-high NS. ES, enrichment score; FD
(E) Correlation plot between ERBB3 and LDHB mRNA expression (L2R) in the 84
(F) Representative LDHB IHC staining in experimental GBMs generated by intracr
(BT463). Scale bar, 100 mm.
(G) Lactate release from ERBB3-low/neg (n = 12) and ERBB3-high (n = 5) NS a
ANOVA). a.u., arbitrary units. Mean ± SEM.
(H) pH of ERBB3-low/neg (n = 20) and ERBB3-high (n = 6) NS standard medium
(I) Extracellular acidification rate (ECAR) in representative ERBB3-high (BT308
(standard medium) (mean ± SEM, n = 4; *p < 0.001, two-way ANOVA). ROT/AA,
(J) Oxygen consumption rate (OCR) of representative ERBB3-high (BT314 and
(standard medium) (mean ± SEM, n = 4, *p < 0.001, two-way ANOVA).
(K) Representative XF PhenoGram obtained by plotting basal OCR versus basal
(L) ATP production by ERBB3-high (BT209 and BT308) and ERBB3-low/neg NS (B
standard medium (*p < 0.05, one-way ANOVA). Mock, PBS-treated cells. Mean
See also Figure S7 and Table S3.
10 Cell Reports 36, 109455, July 27, 2021global phenotype that was significantly more energetic, as
compared with representative ERBB3-low/neg NS (Figures 4I–
4K and S7F). Metabolic hyperactivity of ERBB3-high NS de-
pended on bFGF, as shown by addition of the FGFR inhibitor
BGJ398 to the standard medium, which dramatically quenched
all metabolic parameters (Figures S7G–S7I). Consistent with cell
viability experiments (Figure S5A), the ERBB3 low/neg NSmeta-
bolic activity was unaffected by the FGFR inhibitor (Figures S7H
and S7I).
The hyperactive glycolytic metabolism of ERBB3-high NS was
likely able to fuel a more aggressive cell growth and at the same
time to cause energetic dependency from glycolysis. Indeed,
specific blockade of glucose uptake by theGLUT1 inhibitor 2-de-
oxyglucose abated ATP production, and therefore cell viability, in
ERBB3-high but not in ERBB3-low/neg NS (Figure 4L).
In summary, these data suggest that high levels of ERBB3
expression (supported by miR-205 silencing) enable GSCs to
respond to bFGF with activation of the ERBB3-associated
PI3K/AKT/mTOR pathway. In ERBB3-high GBMs, but not in
those expressing low levels of the receptor, all the downstream
effectors of the mTOR pathway, including genes responsible
for de novo fatty acid synthesis and for glycolytic and mitochon-
drial metabolism, are functionally upregulated, leading to a high-
ly energetic status. This may represent both an advantage and a
liability, as glycolysis inhibition is detrimental for ERBB3-high
GBMs.
ERBB3 overexpression is required for the PI3K/AKT/
mTOR pathway and cell metabolism upregulation
To investigate whether ERBB3 overexpression is required for
PI3K/AKT/mTOR pathway activation and the ensuing metabolic
upregulation induced by bFGF, we treated representative NSs
with MM121 (see above). When added to ERBB3-high NS
growing in standard medium (EGF + bFGF), MM121 caused
downregulation of pivotal mediators of the PI3K/AKT/mTOR
signaling pathway (Figures 5A, 5B, and S8A) and downstreammTOR pathway and metabolic hyperactivation
bolism control.
3-high (left) and ERBB3-neg NS (right) kept in the absence of any growth factor
ells; vinculin, loading control. The same vinculin immunoblot is shown in Fig-
T308) and ERBB3-negNS (BT463) kept in the absence of any growth factor for
rmed in the 84NS-panel microarray.De novo fatty acid synthesis and glycolysis
R, false discovery rate.
NS-panel. Pearson correlation coefficient (R) and p value are reported.
anially transplanted ERBB3-high (BT209 and BT308), -low (BT302), or -neg NS
fter 3 days of culture in standard medium (EGF + bFGF) (*p < 0.05, one-way
after 3 days of culture (*p < 0.001, one-way ANOVA). Mean ± SEM.
and BT209) and ERBB3-low/neg NS (BT302 and BT463) in basal conditions
rotenone/antimycin A; 2-DG, 2-deoxy-d-glucose.
BT209) and ERBB3-low/neg NS (BT302 and BT463) under basal conditions
ECAR values obtained in the experiments shown in (J).
T302 and BT463) 72 h after treatment with the glucose uptake inhibitor 2-DG in
± SEM, n = 6.
(legend on next page)






OPEN ACCESStarget genes, including the key metabolic players GLUT1 and
LDHB (Figure 5C). Consistently, within 24 h of treatment,
MM121 significantly decreased lactate release (Figure 5D) and
impaired both glycolytic and oxidative metabolism (Figures 5E,
5F, S8B, and S8C). In selected experiments (LDHB expression,
lactate release, and medium acidification) overlapping results
were obtained by knocking down ERBB3 with shRNA in repre-
sentative ERBB3-high NS (Figures S8D–S8F). In ERBB3-low/
neg, concomitantly assessed with ERBB3-high NS, MM121 did
not exert any effect (Figures 5D–5F, S8B, and S8C). Conversely,
forced ERBB3 overexpression enabled the representative
ERBB3-neg BT463 to activate themTOR signaling pathway (Fig-
ure 5G), to increase lactate release and medium acidification
(Figures 5H and 5I), and to enhance the glycolytic and oxidative
metabolism (ECAR and OCR) in response to bFGF (Figures 5J
and 5K). The latter responses were fully abolished by MM121
(Figures 5J and 5K). Overall, the cell energy phenotype showed
that ERBB3 overexpression is sufficient to switch NSs from the
ERBB3-low/neg quiescent to the ERBB3-high energetic status,
which can indeed be reverted by ERBB3 inhibition (Figure 5L).Selective ERBB3 inhibition induces ERBB3-high NS
apoptosis
ERBB3-dependent hyperactive metabolism emerged as a liabil-
ity exploitable for destroying ERBB3-high NS. Indeed, prolonged
treatment with MM121 induced cell death, as observed by (1) NS
microscopic features (Figure 6A); (2) impaired cell viability (Fig-
ures 6B and S9A) and appearance of a sub-G0 cell fraction (Fig-
ures S9B and S9C); (3) annexin V incorporation (Figure 6C) and
identification of early and late apoptotic subpopulations (Fig-
ure 6D); (4) transcriptional induction of apoptosis master regu-
lator genes (Figure S9D) and induction of active, cleaved cas-
pase 3 and poly(ADP-ribose) polymerase (PARP) proteinsFigure 5. ERBB3 overexpression is required for PI3K/AKT/mTOR path
(A) Western blot showing inhibition of mTOR signaling pathway effectors at differen
kept in standard medium (EGF + bFGF). Mock, PBS-treated cells; vinculin, loadi
same experiment.
(B) Expression of the mTOR target genes SREBF2, HIF1A, and TFAM 24 h after
medium. Mock, PBS-treated cells. Mean ± SEM, n = 3.
(C) Western blot showing downregulation of Lactate Dehydrogenase B (LDHB) a
ERBB3-high NS (BT308) kept in standard medium (EGF + bFGF). Mock, PBS-tre
(D) Lactate release from ERBB3-high (BT308 and BT314) and ERBB3-low/neg NS
MM121 (*p < 0.05, paired t test). Mock, PBS-treated cells. Mean ± SEM, n = 4.
(E) ECAR in representative ERBB3-high (BT308) and ERBB3-neg NS (BT302), tre
paired t test mock versus MM121-treated NS, p < 0.001). mock, PBS-treated ce
(F) OCR in representative ERBB3-high (BT209) and ERBB3-low NS (BT302), trea
paired t test mock versus MM121-treated NS, p < 0.001). mock, PBS-treated ce
(G) Western blot showing S6 phosphorylation (pS6) and induction of LDHB expr
(BT463_ctrl), kept in the absence of any growth factor for 48 h and treated with b
(H) Lactate release from BT463 transduced with ERBB3 (BT463_ERBB3) or not (
Mean ± SEM, n = 3.
(I) pH of culture media from BT463 as in (H) (*p < 0.001, paired t test). Mean ± SE
(J) ECAR in BT463 transducedwith ERBB3 (BT463_ERBB3) or not (BT463_ctrl), tre
ANOVA, p < 0.005). Mock, PBS-treated cells.
(K) OCR in BT463 as in (J) (mean ± SEM, n = 5; two-way ANOVA, p < 0.005).
(L) Representative XF PhenoGram obtained by plotting basal OCR versus basal E
high NS (BT209 and BT308, red circle) were tested in the same experiment for
induced by MM121.
See also Figure S8.
12 Cell Reports 36, 109455, July 27, 2021(Figures 6E and 6F). A dramatic effect, overlapping to that of
MM121, was obtained by transducing NSs with a specific
ERBB3 shRNA or with miR-205 (Figures 6G, 6H, S9E, and
S9F). Importantly, cell death was induced by MM121 or by
ERBB3 silencing in ERBB3-high but not in ERBB3-low (and
–neg) NS (Figures 6A–6E and S9A–S9H).
Overall, these data show that selective ERBB3 inhibition re-
sults in metabolic downregulation and cell death. These events
specifically occur in ERBB3-high NS, in which ERBB3 overex-
pression is fixed by an inheritable mechanism and likely selected
during tumor progression to provide an advantageous hyperac-
tive metabolism. ERBB3 inhibition is instead ineffective in NSs
that express normal ERBB3 levels, which do not display an
ERBB3-dependent highly energetic metabolic profile.ERBB3 antibodies inhibit ERBB3-high experimental
GBMs
We next investigated the outcome of ERBB3 selective inhibition
by MM121 in preclinical models generated by transplanting
representative ERBB3-high (BT308 and BT209) and ERBB3-
low (BT302) NS. These NSs could efficiently grow subcutis as
well as orthotopically, retaining the parental tumor features,
including ERBB3 nuclear localization in ERBB3-high cases (Fig-
ures 1H, 7A, and S10A).
Treatment of established ERBB3-overexpressing subcutane-
ous tumors withMM121monotherapy over a 3-weeks course re-
sulted in tumor volume stabilization, whereas in mock-treated
mice, the tumor volume increased 5-fold (Figure 7B). Explanted
tumors treated with MM121 revealed a loss of ki67 proliferative
marker expression and appearance of TUNEL-positive
(apoptotic) nuclei (Figures 7C and S10B). MM121 was instead
ineffective in tumors generated by ERBB3-low NS, mirroring
the in vitro response (Figures 7B and S10C). In ERBB3-highway and cell metabolism upregulation
t time points after treatment with or without MM121 in ERBB3-high NS (BT308)
ng control. The same vinculin immunoblot is shown in Figure 3H as part of the
treatment with or without MM121 in ERBB3-high NS (BT308) kept in standard
nd Glucose Transporter 1 (GLUT1) after treatment with or without MM-121 in
ated cells; calnexin, loading control.
(BT373 and BT463) after 2 days of culture in standard medium with or without
ated with or without MM121 for 24 h in standard medium (mean ± SEM, n = 4;
lls; ROT/AA, rotenone/antimycin A; 2-DG, 2-Deoxy-d-glucose.
ted with or without MM121 for 24 h in standard medium (mean ± SEM, n = 4;
lls.
ession in ERBB3-neg BT463 transduced with ERBB3 (BT463_ERBB3) or not
FGF for the indicated times. Vinculin, loading control.
BT463_ctrl) after 3 days culture in standard medium (*p < 0.001, paired t test).
M, n = 3.
ated with or without MM121 in standardmedium (mean ± SEM, n = 5; two-way
CAR values obtained in the experiment shown in (K). Representative ERBB3-
internal comparison. Arrow was added to indicate metabolic downregulation
(legend on next page)






OPEN ACCESStumors, as well as in ERBB3-high NS, MM121 caused downre-
gulation of ERBB3 expression, loss of S6 phosphorylation (a sur-
rogate marker of mTOR pathway activation), and decreased
expression of the key mTOR-target gene LDHB (Figures 7D
and S10D). The same therapeutic protocol, applied to estab-
lished orthotopic tumors generated by luciferase-transduced
ERBB3-high NS (BT308), similarly resulted in a significant tumor
volume reduction, measured as bioluminescence (Figures 7E
and 7F).
Overall, these data indicate that ERBB3-high experimental
GBMs, generated by ERBB3-high NS and reproducing the fea-
tures of the parental tumors, are sensitive to ERBB3 selective in-
hibition and display signs of ERBB3/PI3K/mTOR pathway down-
regulation. Remarkably, this sensitivity is confined to cases that
express high levels of ERBB3, which is associated with the inher-
itable epigeneticmechanismofmiR-205 silencing. This evidence
confirms the principle by which only pathways genetically
selected during tumor progression can be effectively exploited
to target the tumor and advises that patients should be carefully
stratified accordingly as to receive experimental ERBB3 therapy.
DISCUSSION
ERBB3 expression was associated with the GBMproneural sub-
type in the first systematic GBM transcriptional and mutational
classification study (Verhaak et al., 2010). More recently, it was
associated with the so-called type II GBM, identified as a
descendent of OPCs (Wang et al., 2020). ERBB3 was known
for being transcriptionally controlled by SOX10, a factor tightly
required for the development of neural-crest-derived peripheral
glia (in particular myelin-producing Schwann cells, the functional
homolog of oligodendrocytes) (Britsch et al., 2001; Prasad et al.,
2011). Among SOX10 targets, ERBB3 plays a prominent regula-
tory role as, upon NRG1 stimulation, it promotes glial cell fate
specification (Shah et al., 1994). SOX10 then emerged as a tran-
scription factor specifically expressed in themyelinating cell line-
age in both the peripheral and central nervous system, and its
coexpression with its targets ERBB3 (and PDGFR) can be
considered as an unequivocal oligodendroglial-lineage signature
(Laug et al., 2018).Figure 6. Selective ERBB3 inhibition induces ERBB3-high NS apoptos
(A) Micrograph of ERBB3-high (BT308) and ERBB3-low NS (BT373) 24 h after trea
treated cells. Scale bar, 50 mm.
(B) Cell viability of representative ERBB3-high, -low, and -neg NS 48 h after treatm
0.05, paired t test). Mean ± SEM, n = 6.
(C) Cell apoptosis measured as annexin V incorporation (chemiluminescence) aft
BT314) and -low NS (BT373 and BT302) kept in standard medium (*p < 0.001, o
(D) Cell apoptosis measured by flow cytometry of annexin V/DAPI incorporation
without MM121 in standard medium (*p < 0.05, paired t test). Mock: PBS-treated
(E) Percentage of caspase-3 positive cells evaluated by flow cytometry in ERBB3-
in standard medium (*p < 0.05, paired t test). Mock, PBS-treated cells. Mean ± S
(F) Western blot showing activation of PARP (cleaved PARP [cl PARP]) and caspas
without MM121 in standard medium. Mock, PBS-treated cells; calnexin, loading
(G) Micrographs of ERBB3-high NS (BT308 and BT209) 72 h after shERBB3 trans
50 mm.
(H) Cell viability measured in ERBB3-high NS (BT308 and BT209) 24 h and 96 h aft
to complete cell death. Mean ± SEM, n = 10.
See also Figure S9.
14 Cell Reports 36, 109455, July 27, 2021The physiological role of ERBB3 in OPC-derived GBMs seems
hardly adequate to provide a significant advantage in terms of tu-
mor growth and survival. This scenario can dramatically change
in case of ERBB3 genetic alteration, which can unbalance the
downstream signal toward pathways boosting tumor aggres-
siveness. Intratumor inheritable (i.e., evolutionary selectable)
mechanisms of ERBB3 alteration have been so far elusive, as
the ERBB3 gene is seldom affected by sequence alterations or
copy number variations (Jaiswal et al., 2013). In this work, we
report a mechanism of ERBB3 overexpression, based on miR-
205 inactivation. This results from promoter methylation, which
is inheritable, as shown by its transmission from the original tu-
mors to the matched NSs and from these to both NS subclones
and experimental tumors generated by NS transplantation. miR-
205 is known to target ERBB3 in breast cancer cell lines (Iorio
et al., 2009) and to downregulate a narrow set of pro-tumorigenic
and pro-invasive players, such as epithelial-mesenchymal tran-
sition core transcription factors, thus behaving as an oncosup-
pressor (Gandellini et al., 2009; Gregory et al., 2008; Qin et al.,
2013).
A second relevant finding reported in this study is activation of
overexpressed ERBB3 by FGFR3. ERBB3 activation by an RTK
outside the EGFR family is an absolute requirement; indeed,
ERBB3 is kinase inactive, and the other EGFR family members
are not coexpressedwith ERBB3 inGBMs, aswe showedby thor-
ough scrutiny of the 84 NS-panel and the TCGA GBM cohort.
ERBB3 interaction with a receptor belonging to a different RTK
family is not surprising, as it has already been reported with
MET and PDGFR (Engelman et al., 2007; Song et al., 2018). Con-
cerning the ERBB3-FGFR interaction, a previous study character-
izing the outcomesof FGFR2 amplification in lung cancer reported
induction of ERBB3 phosphorylation, indicating that, in principle,
the two receptors can cross-talk (Pearson et al., 2016). Based
on our results, not only is the bFGF/FGFR3 pair required to acti-
vate ERBB3 but also ERBB3 is essential to confer responsiveness
to bFGF. Like ERBB3, FGFR family activity has been associated
with oligodendroglial early cell fate determination, and FGFR3 is
known to counteract terminal differentiation (Fortin et al., 2005).
Therefore, ERBB3-FGFR3 cooperation occurring in OPC-derived
GBMs seems rooted in the innate properties of the cell of origin.is
tment with or without MM121 in standard medium (EGF + bFGF). Mock, PBS-
ent with or without MM121 in standard medium. Mock, PBS-treated cells. (*p <
er treatment with or without MM121 of representative ERBB3-high (BT308 and
ne-way ANOVA). Mean ± SEM, n = 8.
in ERBB3-high (BT308) or ERBB3-low NS (BT373) 24 h after treatment with or
cells.
high (BT308) or ERBB3-low NS (BT373) after treatment with or without MM121
EM, n = 3.
e-3 (casp-3) in a representative ERBB3-high NS (BT308) after treatment with or
control.
duction (bright field and fluorescein isothiocyanate [FITC] channel). Scale bar,
er shERBB3 transduction ( *p < 0.001, paired t test). n.a., not assessable owing
(legend on next page)






OPEN ACCESSFixation of ERBB3 overexpression by miR-205 inactivation could
strongly contribute to retaining OPCs in an early stage, in which
hyperactive signaling activities mediated by ERBB3 can boost
high metabolic rate and vigorous cell expansion.
ERBB3 is known to be a privileged platform for PI3K activation
(Schulze et al., 2005). This, in turn, activates the AKT/mTOR
pathway, a master regulator of macromolecule biosynthesis,
which is a prerequisite for cell growth, duplication, and prolifera-
tion (Goncalves et al., 2018; Saxton and Sabatini, 2017). As we
showed, in the presence of overexpressed ERBB3, bFGF
powerfully activates the PI3K/AKT/mTOR pathway, leading to
upregulation of a complex metabolic network including the
glycolytic pathway as a key element (Goncalves et al., 2018).
As it is known, enhanced tumor anaerobic glycolysis in normoxic
conditions (the renowned Warburg effect) is not merely an ineffi-
cient way to generate ATP; rather, it causes an accumulation of
glycolytic pathway intermediates and end products, with the
latter transformed by mitochondrial metabolism and all contrib-
uting to amino acid, nucleotide, and lipid synthesis (Zhu and
Thompson, 2019). In ERBB3-high NS, together with glycolytic
metabolism, increased mitochondrial activity was also evident,
further highlighting the importance of the mitochondrial pathway
in GBM, which was previously associated with FGFR3-TACC
gene fusion (Frattini et al., 2018) and proposed as a therapeutic
target (Shi et al., 2019).
The keen global metabolic enhancement in ERBB3-overex-
pressing GBM is likely a double-edge sword. On the one hand,
it supports aggressive tumor growth, testified by the significantly
reduced overall survival of patients overexpressing ERBB3 in both
the whole 84 NS-panel and proneural TCGA patient cohorts. On
the other hand, the mTOR pathway and metabolic shutdown
caused by targeting ERBB3 with specific antibodies (seribantu-
mab/MM121) was sufficient to induce cell death. This scenario
represents a typical case of ‘‘oncogene addiction,’’ in which an
alteration selectedduring tumor evolution (ERBB3overexpression
fixed by epigenetic miR-205 inactivation) confers cellular depen-
dence on protein activity and destructive outcomes when the
latter is impaired (Sharma and Settleman, 2007).
These observations are crucial to guide the possible exploi-
tation of ERBB3 as a GBM therapeutic target. As we showed
in NSs and experimental tumors, ERBB3 inhibition is effective
only in cases for which ERBB3 overexpression is sustained
by miR-205 inactivation but not in those for which ERBB3 is ex-
pressed at normal levels. Identification of patients eligible for
targeted therapy is always critical and requires appropriate bio-Figure 7. ERBB3 antibodies inhibit ERBB3-high experimental GBMs
(A) Representative ERBB3 IHC staining in tumors generated by subcutaneous tran
ERBB3 nuclear staining (arrows). Scale bar, 100 mm.
(B) Growth curves of established tumors, generated by subcutaneous transplant o
MM121 for 21 days (n = 6/group; *p = 0.0001, one-way ANOVA). Mock, PBS-tre
(C) Representative ki67 and TUNEL stainings of the same ERBB3-high tumors a
positive cells (n = 10 HPF/condition; *p = 0.008, Kolmogorov-Smirnov test) (right
(D) Representative IHC staining of ERBB3, phospho-S6 (pS6), and LDHB in the s
(E) Luciferase radiance intensity in representative mice intracranially transplanted
or without MM121. Mock, PBS-treated mice.
(F) Bioluminescence measured in mice as in (E) (n = 6/group) (*p < 0.05, two-way
See also Figure S10.
16 Cell Reports 36, 109455, July 27, 2021markers, whose definition can be difficult especially in the case
of analogic variables such as protein expression levels. In the
case of ERBB3 overexpression, a meaningful surrogate
biomarker is ERBB3 nuclear localization, which was previously
described and explained by the presence of an uncommon nu-
clear import signal in the ERBB3 sequence (Reif et al., 2016).
Such nuclear accumulation can merely reflect excess protein
production or hide still obscure functional properties linked
with the ERBB3 ability to modulate gene transcription, which
could further explain the dramatic effect of ERBB3 overexpres-
sion on the GBM phenotype.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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Antibodies
anti-ERBB3 (1B2) antibodies Cell Signaling Technology #4754; RRID:AB_10691324 (WB 1:1000, IF 1:100)
anti-ERBB3 (2F12) antibodies Millipore #05-390; RRID:AB_309713 (4 mg/ml)
anti-ERBB3 antibodies Sigma-Aldrich #ab-1328; RRID:AB_10621903 (IHC 1:100)
anti-ERBB3 antibodies ATLAS antibodies #HPA045396; RRID:AB_2679312 (IHC 1:20)
anti-ERBB3-PE (REA508) antibodies Miltenyi Biotec GmbH #130-107-899; RRID:AB_2651655 (1:20)
anti-ERBB3-APC (1B4c3) antibodies Biolegend #324708; RRID:AB_2099567 (1:100)
anti-phospho-ERBB3 Tyr1197 antibodies Cell Signaling Technology #4561; RRID:AB_2099707 (WB 1:1000)
anti-phospho-ERBB3 Tyr1222 antibodies Cell Signaling Technology #4784; RRID:AB_659920 (WB 1:1000)
anti-phospho-ERBB3 Tyr1289 antibodies Cell Signaling Technology #4791; RRID:AB_2099709 (WB 1:1000)
anti-ERBB2 (e2-4001) antibodies Thermo Fisher Scientific MA5-13105; RRID:AB_10988194 (WB 2 mg/ml)
anti-ERBB2 (Trastuzumab) antibodies Roche RRID:AB_2489608 (IP 2 mg/ml)
anti-ERBB2 antibodies Agilent A0485; RRID:AB_2335701 (IHC 1:600)
anti-ERBB2-FITC (5D3) antibodies Biolegend #324404; RRID:AB_756120 (1:20)
anti-ERBB4 (111B2) antibodies Cell Signaling Technology #4795; RRID:AB_2099883 (WB 1:1000, IP 1:50)
anti-ERBB4-PE antibodies R&D System #AF1131; RRID:AB_354620 (1:20)
anti-EGFR (D38B1) antibodies Cell Signaling Technology #4267; RRID:AB_2246311 (WB 1:1000, IP 1:50)
anti-EGFR (Ab10 111.6) antibodies Thermo Fisher Scientific #OPA1-10100; RRID:AB_325381 (IHC 1:100)
anti-EGFR-PE (EGFR.1) antibodies BD Bioscience #555997; RRID:AB_396281 (1:20)
anti-FGFR1 antibodies Cell Signaling Technology #3472; RRID:AB_2103374 (WB 1:1000)
anti-FGFR2 (D4H9) antibodies Cell Signaling Technology #11835; RRID:AB_2797742 (WB 1:1000)
anti-FGFR2-APC (98725) antibodies R&D System #FAB684A; RRID:AB_894678 (1:10)
anti-FGFR3 (2H10B4) antibodies NovusBio NBP2-52468; RRID:AB_2782964 (WB 1:500, IF
1:100)
anti-FGFR3 (OTI1B10) antibodies NovusBio NBP2-45716 (IP 5 mg/ml)
anti-FGFR3-APC (136334) antibodies R&D System #FAB766A; RRID:AB_11129249 (1:20)
anti-FGFR4 antibodies Cell Signaling Technology #2894; RRID:AB_2293993 (WB 1:1000)
anti-FGFR4-APC (240929) antibodies R&D System #FAB6852A; RRID:AB_10971830 (1:20)
anti-PDGFRA (D1E1E) antibodies Cell Signaling Technology #3174; RRID:AB_2162345 (WB 1:1000, IP 1:50)
anti-PDGFRA-PE (16A1) antibodies Biolegend #323506; RRID:AB_2268113 (1:10)
anti-PDGFRB (C82A3) antibodies Cell Signaling Technology #4564; RRID:AB_2236927 (WB 1:1000, IP 1:50)
anti-MET (DL21) antibodies Prat et al., 1998 (WB 1:1500, IP 1:50)
anti-MET (DO24) antibodies Prat et al., 1998 (IP 5 mg/ml)
anti-HGF R/MET-PE-Cy7 (95106) antibodies R&D System #MAB3582; RRID:AB_884334 (1:20)
anti-KIT antibodies Cell Signaling Technology #3074; RRID:AB_1147633 (WB 1:1000, IP 1:50)
anti-KIT-APC (104D2) antibodies Immunological Science #MAB-9117APC; RRID:AB_2892615
anti-NTRK2 antibodies R&D System #AF1494; RRID:AB_2155264 (WB 0.5 mg/ml, IP
5 mg/ml)
anti-NTRK2-AlexaF647 (72509) antibodies R&D System #FAB3971R; RRID:AB_2892614
anti-pan-phospho-tyr antibodies Millipore #05-321; RRID:AB_309678 (WB 1:1000)
anti-NEDD4 antibodies Bethyl #A303-254A-T; RRID:AB_10952871 (WB 1:1000)
anti-NRDP1 antibodies NovusBio #NB100-583; RRID:AB_2269715 (WB 1:10000)
anti-MAP2 antibodies Cell Signaling Technology #4542; RRID:AB_10693782 (WB 1:1000)
anti-BCL2 antibodies Cell Signaling Technology #4223; RRID:AB_1903909 (WB 1:1000)
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anti-phospho-42/44 MAPK antibodies Cell Signaling Technology #4370; RRID:AB_2315112 (WB 1:1000)
anti-phospho-AKT antibodies Cell Signaling Technology #3787; RRID:AB_331170 (WB 1:1000)
anti-phospho-FRS2 Tyr436 antibodies Cell Signaling Technology #3861; RRID:AB_2231950 (WB 1:500)
anti-phospho-mTOR (Ser2448) antibodies Cell Signaling Technology #2971; RRID:AB_330970 (WB 1:1000)
anti-phosphoRAPTOR(Ser792) antibodies Cell Signaling Technology #2083; RRID:AB_2249475 (WB 1:1000)
anti-RAPTOR (E60O3A) antibodies Cell Signaling Technology #2280, RRID:AB_561245 (WB 1:1000)
anti-phospho-S6 antibodies Cell Signaling Technology #4858; RRID:AB_916156 (WB 1:1000, IHC 1:100)
anti-S6 antibodies Cell Signaling Technology #2217; RRID:AB_331355 (WB 1:1000)
anti-phospho-4EBP1 (Thr37/46) antibodies Cell Signaling Technology #2855; RRID:AB_560835 (WB 1:1000)
anti-LDHB antibodies Abcam #ab52488; RRID:AB_2134961 (WB 1:5000, IHC
1:500)
anti-GLUT1 (D3J3A) antibodies Cell Signaling Technology #12939; RRID:AB_2687899 (WB 1:1000)
anti-cleaved PARP antibodies Cell Signaling Technology #9541; RRID:AB_331426 (WB 1:1000)
anti-cleaved caspase 3 (asp175) antibodies Cell Signaling Technology #9661, RRID:AB_2341188
anti-b-actin antibodies Cell Signaling Technology #8457; RRID:AB_10950489 (WB 1:1000)
anti-calnexin antibodies Cell Signaling Technology #2679; RRID:AB_2228381 (WB 1:1000)
anti-TATA binding Protein antibodies Millipore #05-1531, RRID:AB_11212675
anti-GAPDH antibodies Abcam #ab9483; RRID:AB_307273
anti-vinculin antibodies Sigma-Aldrich #V9131; RRID:AB_477629
anti-ki67 antibodies Agilent M724001-2; RRID:AB_2631211
Biological samples
human glioblastoma tissues Istituto Neurologico C. Besta https://www.istituto-besta.it/
Chemicals, peptides and recombinant proteins
bFGF PeproTech #100-18B, 20 ng/ml
EGF Sigma-Aldrich E5036, 20 ng/ml
NRG1 PeproTech #100-03, 50 ng/ml
PDGFBB PeproTech #100-14B, 20 ng/ml
HGF PeproTech #100-39H, 20 ng/ml
BDNF PeproTech #450-02, 20 ng/ml
SCF1 PeproTech #300-07, 20 ng/ml
Seribantumab (MM121) Merrimack in vitro: 50 mg/ml; in vivo: 30 mg/kg
2-Deoxy-D-glucose (2-DG) Sigma-Aldrich D3179, 50mM
BGJ398 Selleckchem #S2183, 5nM
5-aza-20-deoxycytidine (50 AZA) Sigma-Aldrich #A3656, 5mM
Critical commercial assays
GenePrint 10System Promega B9510
All Prep DNA/RNA Mini kit QIAGEN #80284
miRNeasy Mini kit QIAGEN #217084
RNeasy Mini kit QIAGEN #74004
Maxwell RSC miRNA Tissue kit Promega #AS4500
Platinum Taq Hot-Start DNA Polymerase Thermo Fisher Scientific #14966001
Platinum SuperFi II DNA Polymerase Thermo Fisher Scientific #12361010
Illumina TotalPrep RNA Amplification Kit Illumina AMIL1791
EZ-DNA Methylation Gold Kit ZYMO Research #D5008
ERBB3/CEN 12 Dual Color Probe Zytovision #Z-2056-200
Nick translation reagent kit Abbot Molecular Inc. #07J00-001
TransIT-X2 Dynamic Delivery System MirusBio #miR6003
Protein A Mag Sepharose GE Healthcare #28951378
(Continued on next page)
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DeadEnd Fluorometric TUNEL System Promega #G3250
Duolink PLA Technology Sigma-Aldrich #DUO92101
Lactate-GloAssay Promega #J5021
Glycolytic Rate Assay Agilent #103344-100
XF Cell Mito Stress Agilent #103015-100
Cultrex BME PathClear Tema Ricerca #3533-010-02
CellTiter-Glo Promega #G7570
RealTime-Glo Annexin V Apopt and Nec Asay Promega #JA1011
eBioscience Annexin V Apopt Detection Kit ThermoFisher Scientific #BMS500FI-20
Deposited data
gene expression dataset this paper http://data.mendeley.com/login?
redirectPath=/datasets/tyjf6km8y6/draft?a=
505d1617-dc0d-4c42-b9c6-5a558578346c
gene expression dataset this paper GEO: GSE178236
rawdata for western blots in Figures 2, 3, 4, 5, and 6 this paper http://data.mendeley.com/login?
redirectPath=/datasets/tyjf6km8y6/draft?a=
505d1617-dc0d-4c42-b9c6-5a558578346c
Experimental models: Cell lines
glioblastoma neurospheres this paper Table S1
colosphere M049 Luraghi et al., 2018 N/A
U87MG ATCC ATCC HTB-14
A549 ATCC ATCC CCL-185
A2780 ECACC 93112519-1VL
A375 ATCC ATCC CRL-1619
K562 NCI-60 cancer panel N/A
OE21 ECACC 96062201-1VL
MDA468 NCI-60 cancer panel N/A
HeLa ATCC ATCC CCL-2
T47D NCI-60 cancer panel N/A
MCF7 NCI-60 cancer panel N/A
BT474 DMSZ ACC 64
Experimental models: Organisms/strains
NOD.CB17-Prkdcscid/J Charles River Laboratories N/A
Oligonucleotides
primers this paper Table S4
ERBB3 Thermo Fisher Scientific Hs00187734_cn
CDKN2A Thermo Fisher Scientific Hs03714372_cn
EGFR Thermo Fisher Scientific Hs04942325_cn
HGF Thermo Fisher Scientific Hs02789622_cn
PDGFRA Thermo Fisher Scientific Hs05935655_cn
PTEN Thermo Fisher Scientific Hs02599450_cn
CDK4 Thermo Fisher Scientific Hs01071103_cn
CDK6 Thermo Fisher Scientific Hs04934380_cn
MDM2 Thermo Fisher Scientific Hs02904108_cn
MIR205HG Thermo Fisher Scientific Hs07483345_cn
RNaseP CNV Thermo Fisher Scientific 4403328
ERBB3 Thermo Fisher Scientific Hs00176538_m1
SNHG5 Thermo Fisher Scientific Hs05037597_s1
(Continued on next page)
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TFAM Thermo Fisher Scientific Hs00273372_s1
HIF1A Thermo Fisher Scientific Hs00936368_m1
SREBF2 Thermo Fisher Scientific Hs01081784_m1
APAF1 Thermo Fisher Scientific Hs00559441_m1
BAD Thermo Fisher Scientific Hs00188930_m1
BAK1 Thermo Fisher Scientific Hs0083876_g1
BAX Thermo Fisher Scientific Hs00180269_m1
BID Thermo Fisher Scientific Hs01026792_m1
BIM (BCL2L11) Thermo Fisher Scientific Hs00708019_s1
BIK Thermo Fisher Scientific Hs00154189_m1
HRK Thermo Fisher Scientific Hs02621354_s1
NOXA (PMAIP1) Thermo Fisher Scientific Hs00560402_m1
PUMA (BBC3) Thermo Fisher Scientific Hs00248075_m1
B2M Thermo Fisher Scientific Hs00984230_m1
miR205 Thermo Fisher Scientific hsa-miR 205_000509
miR22 Thermo Fisher Scientific hsa-miR 22_000398
miR125a-5p Thermo Fisher Scientific has-miR 125a-5p_002198
miR125b Thermo Fisher Scientific has-miR 125b_000449
miR148a Thermo Fisher Scientific has-miR 148a_000470
miR152 Thermo Fisher Scientific has-miR 152_000475
RNU48 Thermo Fisher Scientific 001006
Recombinant DNA
human ERBB3 (pReceiver-Lv105-ERBB3) GeneCopoeia #Y2798
human ERBB3 shRNA lentiviral particle OriGene Technologies Locus ID 2065, TL320343V
human FGFR3 shRNA lentiviral particle OriGene Technologies Locus ID 2261, TL320355V
empty shRNA vector OriGene Technologies TL30021V
miRZIP Lentiviral-based anti-microRNAs System Bioscience #MZIP 205PA-1
anti-miR-205-5p miRCURY LNAinhibitor QIAGEN #4101508-001
Software and algorithms
cBioPortal site for Cancer Genomics Cerami et al., 2012 http://www.cbioportal.org/
GlioVis data portal Bowman et al., 2017 http://gliovis.bioinfo.cnio.es/
Glioblastoma BioDiscovery Portal (miRNA) NCI http://gbm-biodp.nci.nih.gov/
The Human Protein Atlas Uhlen et al., 2010 http://www.proteinatlas.org
GraphPad Prism 8.3.0 GraphPad software https://www.graphpad.com:443/
Laboratory Assistance Suite (LAS) Baralis et al., 2012 https://las.ircc.it:443/las/laslogin/
StudyLog Version 4.2.1.3 StudyLog Systems Inc. N/A
Chromas Lite 2.01 software Technelysium http://technelysium.com.au/wp/chromas/
COSMIC Sanger Institute https://cancer.sanger.ac.uk/cosmic
Nearest Template Prediction algorithm Hoshida, 2010 http://cloud.genepattern.org/
Caleydo 3.1.5 JKU Visual Data Science Lab http://caleydo.org/
GSEA software v.4.0.2 Broad Institute http://www.gsea-msigdb.org/gsea/
index.jsp
GEDAS software Fu and Medico, 2007 https://sourceforge.net/projects/gedas/
TargetScanHuman 7.2 Lewis et al., 2005 http://www.targetscan.org/vert_72/
CytoVision software Leica N/A
Summit 4.3 software Beckman Coulter N/A
Amnis IDEAS 6.2 image analysis software Luminex N/A
Image Lab software Biorad N/A
Wave Controller 2.6 software Agilent N/A








Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Carla Boc-
caccio (carla.boccaccio@ircc.it).
Materials availability
Neurospheres are available upon institutional material transfer agreement approval after request by qualified academic investigators
for non-commercial purposes.
Data and code availability
d The gene expression dataset (microarray) generated during this study has been deposited in the Gene Expression Omnibus Data-
base (GEO) and is publicly available as of the date of publication. Accession number is listed in the Key resources table. Gene expres-
sion dataset and original western blot images for Figures 2, 3, 4, 5 and 6 have been deposited at Mendeley and are publicly available
as of the date of publication. The DOI is listed in the Key resources table.
d This paper does not report original code.
d Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Neurosphere (NS) derivation from human patients
We derived 84 cultures enriched in stem-like cells (i.e., neurospheres, NS; hereafter overall referred as 84 NS-panel) starting from
surgical samples of consecutive primary GBMs obtained at Fondazione IRCCS Istituto Neurologico C. Besta (see Table S2 for pa-
tient’s details), according to a protocol approved by the institutional Ethical Committee, as previously described (De Bacco et al.,
2012). NS were propagated at clonal density in standard medium containing human bFGF (20 ng/ml, PeproTech) and EGF (20 ng/
ml, Sigma-Aldrich).
Neurosphere subcloning and cell treatment with growth factors
Subclones from ERBB3-high NS were obtained by seeding single cell in standard medium in low-adherent conditions and were sta-
bilized on average after 2 months. NS pseudo-differentiation was induced by culturing cells in a medium deprived of growth factors
and supplemented with 1% FBS (Sigma-Aldrich) in pro-adherent conditions for 4 days. For characterization of growth factor
biochemical and biological activities, cells were previously kept in the absence of any growth factor for 48 h; bFGF (20 ng/ml),
NRG1 (50 ng/ml), BDNF (20 ng/ml), SCF-1 (20 ng/ml), HGF (20 ng/ml) and PDGFBB (20 ng/ml) (PeproTech), EGF (20 ng/ml,
Sigma-Aldrich) were added as indicated. The colorectal cancer stem-like cells M049 (colosphere) (Luraghi et al., 2018) was used
as positive control for NRG1 activation. Human cell lines (U138MG, A549, A2780, A375, K562, OE21, MDA468, BT474, HeLa,
T47D and MCF7), used as positive controls of RTK expression and activation, were kept in culture according to manufacturer’s in-
structions (see Key resources table for details), and re-authenticated soon before experiments by short tandem repeated profiling
(GenePrint 10System, Promega).
Generation of experimental tumors
All animal studies were performed according to ethical regulations and protocols approved by the Italian Ministry of Health. Exper-
iments were performed on 6-8 weeks old male NOD.CB17-Prkdcscid/J mice (Charles River Laboratories). Mice were housed at a
maximum of 6 per cage with a 12 h light/dark cycle at 22C, and were monitored at a minimum of twice weekly for general perfor-
mance status. NS intracranial transplantation was conducted as previously described (De Bacco et al., 2016). Briefly, 2.5 3 105
dissociated cells were stereotactically injected into themouse brain (coordinates usedwere as follows: 0.7mmanterior frombregma,
2 mm lateral from the midline and 2 mm below the pial surface). Mice were monitored and sacrificed at the appearance of evident
suffering signs. For subcutaneous transplantation, 2-53 105 cells were resuspended in 100 ml 1:1 v/v PBS/Matrigel (BD Biosciences)
and injected into the right flank. Tumor diameters were evaluated twice/week by caliper and tumor volume was calculated using the
formula: 4/3p3 (d/2)23 (D/2), where d and D are the minor and the major tumor axis, respectively. Mice were euthanized when xe-
nografts’ volume reached 1600 mm3, or they displayed signs of distress, or weight loss R 20%.
Treatment of experimental tumors with MM121
For treatment of experimental subcutaneous GBMs with the specific anti-ERBB3 antibody MM121 (Merrimack) (Schoeberl et al.,
2017), mice were randomized in mock-treated or MM121-treated groups starting from awider cohort of established tumors (average
volume 150 mm3), using the Laboratory Assistant Suite (Baralis et al., 2012). For treatment of intracranial GBMs, ERBB3-high NS
(BT308) were engineered to express luciferase and GFP as previously described (De Bacco et al., 2016) and in vitro bioluminescence
was verified. Intracranial injection (as described above), tumor monitoring and treatment were performed by an external Contract
Research Organization (Accelera srl, Italy). Mice were monitored by bioluminescence imaging (IVIS Lumina System, Caliper LifeCell Reports 36, 109455, July 27, 2021 e5
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cohort and using StudyLog Version 4.2.1.3 (StudyLog Systems Inc.). For both subcutaneous and intracranial experimental
GBMs, MM121 (30 mg/kg) was administered by intraperitoneal injection twice/week; mock-treated mice received PBS. At least 6
mice/group were used, in order to identify significant therapeutic responses with a statistical power of 90% (calculated by consid-
ering: volume variations of ± 15% as random, volume variation of at least 20% as a therapeutic effect and a statistical significance of
p = 0.05).
Patients’ data and survival analysis
Clinical data of patients that generated the 84 NS-panel (Table S2) were obtained according to the requirements of the institutional
Ethical Committee, and analyzed after patients de-identification. For the TCGA GBM cohort: (1) genetic data for correlation studies
were obtained from the public cBioPortal website (https://www.cbioportal.org/; Cerami et al., 2012) and were selected as follow:
Glioblastoma Multiforme TCGA Firehose Legacy; samples with mutations, CNV and expression data (n = 136). (2) Gene expression,
classification and survival data were obtained from the public TCGA GBM Dataset (http://gliovis.bioinfo.cnio.es/); only primary un-
treated GBMswere included (n = 479). (3) miR expression data were obtained from the public TCGAGBMDataset (http://gbm-biodp.
nci.nih.gov/) (n = 339). (4) Immunohistochemical evaluation of EGFR family members in public tumors was obtained from the Human
Protein Atlas (http://www.proteinatlas.org; Uhlen et al., 2010). Survival curves were calculated using log-rank (Mantel-Cox) and Wil-
coxon test with Prism v8.0 software (GraphPad). Patients originating the 84 NS-panel were defined as ERBB3-high when matched
with NS displaying ERBB3mRNA log2ratio > 2.5; patients in the TCGAGBM cohort were defined as ERBB-high when ERBB3mRNA
level was in the upper quartile.
METHOD DETAILS
NS treatment with inhibitors
For in vitro ERBB3 targeting, the specific anti-ERBB3 antibody MM121 (Merrimack) (Schoeberl et al., 2017) was used at the dose of
50mg/ml in single administration, according tomanufacturer’s instructions. For FGFR inhibition, the pan-FGFR inhibitor BGJ398 (Sell-
eckchem) was used at the dose of 5 nM. For glucose uptake inhibition, NS were treated with 2-Deoxy-D-glucose (2-DG, 50 mM,
Sigma-Aldrich). For methylation inhibition, cells were treated with the demethylating agent 5-aza-20-deoxycytidine (50 AZA, 5 mM,
Sigma-Aldrich). In all the above treatments, NS were kept in complete standard medium containing EGF and bFGF (20 ng/ml
each); mock-treated cells received equal volume of PBS or DMSO.
Nucleic acid extraction and retro-transcription
From NS, nucleic acids were extracted using All Prep DNA/RNAMini Kit (QIAGEN) according to manufacturer’s instructions with mi-
nor modifications for preserving miRNAs. Briefly, 1.5 volumes of Absolute ethanol were used in the RNA precipitation step and wash
buffer RW1 was replaced by RWT buffer (QIAGEN). In some experiments either miRNeasy Mini Kit (QIAGEN) or RNeasy Mini Kit
(QIAGEN) were used following manufacturer’s instructions. In parental and experimental GBMs, RNA and miRNAs were extracted
from 10mm thick formalin-fixed paraffin embedded (FFPE) sections with Maxwell RSC miRNA Tissue kit and apparatus (Promega)
according to manufacturers’ instructions. Purified mRNA and miRNAs were reverse transcribed starting from 150 or 250ng of total
RNA and using High-Capacity cDNA or TaqMan microRNA Reverse Transcription Kit and specific microRNA primers, respectively
(Thermo Fisher Scientific).
Gene copy number evaluation
Gene copy number analysis was assessed by real-time PCR, using TaqMan Universal PCR Master MIX and the ABI PRISM 7900HT
sequence detection system (Thermo Fisher Scientific). Primers for TaqMan copy number assays are reported in the Key resources
table. Relative gene copy number data were calculated by normalizing against endogenous control (RNaseP). A normal diploid hu-
man gDNA (293T cell line, ATCC) was used as calibrator to obtain the DDCt. The copy number of each gene was calculated with the
formula 2x2-DDCt. To discriminate between real EGFR amplification and chr7 polysomy, the calculated copy number was normalized
against the copy number of a gene mapped on chr7 and usually not amplified (HGF). EGFR amplification is defined when EGFR copy
number is > 3 + HGF copy number.
Gene sequencing
PCR products used for gene sequencing were amplified either from gDNA (TERT promoter, IDH1, MIR205HG, PIK3CA, TP53 and
PTEN) or from cDNA (ERBB3 and EGFR ‘‘CNS specific’’ alterations corresponding to aa 108/289/598 and surrounding sequences)
using Platinum Taq DNA Polymerase (Thermo Fisher Scientific); TERT promoter amplification was obtained using Platinum SuperFi
DNA Polymerase plus GC enhancer (Thermo Fisher Scientific). Specific primer pairs used are listed in Table S4 and De Bacco et al.
(2012). PCR conditions for IDH1,MIR205HG, PIK3CA, PTEN and TP53were as follows: 95C for 3min; 33 [95C for 15 s, 64C for 30
s, and 70C for 1min]; 33 [95C for 15 s, 61C for 30 s, and 70C for 1min]; 33 [95C for 15 s, 58C for 30 s, and 70C for 1min]; 373
[95C for 15 s, 57C for 30 s, and 70C for 1 min]; and 70C for 5 min. PCR conditions for EGFR and ERBB3were as follows: 95C for
3 min; 403 [95C for 30 s, 63C for 30 s, and 72C for 30 s]; and 72C for 5 min. PCR conditions for TERT promoter were as follows:e6 Cell Reports 36, 109455, July 27, 2021
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ProStar 1-Step (Illustra) according to manufacturer’s instructions. Cycle sequencing was carried out using BigDye Terminator v3.1
Cycle Sequencing kit (Thermo Fisher Scientific). Sequencing products were purified using Agencourt CleanSeq (Agencourt Biosci-
ence, Beckman Coulter) and analyzed on a 3730 DNA Analyzer ABI capillary electrophoresis system (Thermo Fisher Scientific). Se-
quences were then analyzed with Chromas Lite 2.01 software (http://technelysium.com.au/wp/chromas/) and compared with refer-
ence sequences from the Homo sapiens assembly GRCh37 (February 2009). All identified mutations were then compared with those
reported in the Catalogue Of Somatic Mutations In Cancer (COSMIC, https://cancer.sanger.ac.uk/cosmic).
Transcriptome analysis
For gene expression profiling of the 84 NS-panel, biotin-labeled cRNA was synthesized from 500ng of total RNA with the Illumina
TotalPrep RNA Amplification Kit and hybridized on Human HT-12 v4 BeadChip (Illumina), according to manufacturer’s instructions.
The chip was labeled with streptavidin-Cy3 and the fluorescent signal was scanned with the Illumina BeadArray Reader. Raw data
were summarized and cubic-spline normalized with the GenomeStudio software (Illumina). Data filtering and log2ratio transformation
were carried out with Excel (Microsoft). Whenmultiple probesmapped on the same gene, probe displaying the highest average signal
was reported.
NS classification according to Wang et al. (2017) was performed by the tree way methodology available at http://gliovis.bioinfo.
cnio.es/; NS classification according to Wang et al. (2020) was performed using Nearest Template Prediction algorithm (Hoshida,
2010) available at https://cloud.genepattern.org/. Correspondences between NS classifications were represented using Caleydo
3.1.5. Gene set enrichment analysis was performed using GSEA software v.4.0.2. Genes sets used in this study are reported in Table
S3. Clustering and data representation were performed with the GEDAS software (Fu & Medico, 2007).
Quantitative Real-Time PCR (qPCR)
Real-time PCR for evaluation of gene mRNA andmiRNA expression was performed using primer and probe sets (Thermo Fisher Sci-
entific) listed in the Key resources table, with TaqMan Universal PCR Master Mix and an ABI PRISM 7900HT sequence detection
system (Thermo Fisher Scientific). Expression levels were normalized against endogenous controls (b-actin and b2 microglobulin
for genemRNA; RNU48 for miRNA); control cells were used as calibrators. Expression levels were reported as 40-Ct or as fold versus
control cells, and are the mean ± SEM of two independent experiments in triplicate.
Bisulfite treatment and methylation analysis
200ng of gDNA were bisulfite converted using the EZ-DNA Methylation Gold kit (ZYMO Research) according to manufacturer’s
instructions. Amplification was performed in replicate in a final volume of 20 mL using 1.5 mM of Mg, 300 nM of dNTP, 200 nM
of primer mix, and 0.4 Unit of Platinum Taq (Invitrogen), with 45 cycles using 58C or 60C as annealing temperature for
miR205 promoter and miR205HG respectively. 10 mM forward primer, 10 mM biotinylated Tag and 1 mM reverse primer were
used for primer mix (primer sequences are reported in Table S4). Amplification products were purified and annealed with the
sequencing primer using the pyromark Q24 Workstation, according to manufacturer’s protocol, and were then sequenced on py-
romark Q24 (QIAGEN). For evaluation of MGMT promoter methylation, NS gDNA was analyzed with BEAMing methodology as
previously described (Pietrantonio et al., 2014). Briefly, MGMT amplification was first obtained using the Platinum Taq (Life tech-
nologies) and specific primers listed in Table S4. PCR products were diluted (1:20000) and a second amplification step allowing
physical separation and independent amplification of different templates was performed. PCR emulsion breaking and hybridization
(sequences in Table S4) were carried out using Inostics reagents. Fluorescence was assessed on a CyAN flow-cytometer
(Beckam-Coulter). The percentage of methylation was evaluated as follow: methylated specific signals/(methylated + unmethy-
lated specific signals).
FISH analysis
For evaluation of ERBB3 gene amplification or translocation, FISH analysis was performed using ERBB3/CEN 12 Dual Color Probe
(Zytovision), including a green fluorochrome probe specific for the alpha satellite centromeric region of chromosome 12 (D12Z3)
and an orange fluorochrome probe specific for the human ERBB3 gene (12q13.2-q13.3). For evaluation of the MIR205HG genomic
region (chr1:209,428,823-209,432,549, hg38), FISH analysis was performed using RP11-927D11 (chr1:209,409,153-209,605,505)
and the centromeric clones RP11-57I17 (chr1:207,554,754-207,751,766) and RP11-547I7 (chr1:190,352,905-190,488,640), kindly
provided by Prof. M. Rocchi (University of Bari). Briefly, BAC clones DNA were isolated and fluorescent dye incorporation was
performed using Nick translation reagent kit [SpectrumGreen (RP11-927D11), SpectrumRed (RP11-57I17), or SpectrumAqua
(RP11-547I7) conjugated dUTP] (Abbot Molecular inc.). FISH was carried out on interphase cells prepared according to standard
techniques. Cells were incubated with the probe for 10 min at 75C for co-denaturation and placed in a humidified chamber at
37C overnight for the hybridization step. After washing with ISH Stringent Wash Buffer (Agilent), chromatin was counterstained
with DAPI 150ng/ml (Zytovision). An average of 100 cells was analyzed using an Olympus BX61 microscope and CytoVision soft-
ware. ERBB3 and miR205 status was defined by calculating the mean gene copy number (ratio copy number/nuclei), and consid-
ered increased if R 3.Cell Reports 36, 109455, July 27, 2021 e7
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For identification of putativemiRNAs targeting ERBB3, the ERBB3 30 UTR sequence fromensembl (http://www.ensembl.org//useast.
ensembl.org/?redirectsrc=//www.ensembl.org%2F, ENST00000267101.3) was analyzed with TargetScanHuman 7.2 (http://www.
targetscan.org/vert_72/). miRNAs highly conserved and with a high context score (Agarwal et al., 2015; Lewis et al., 2005) were
selected for further analysis.
NS transfection and transduction
For transfection with antagomiR-205 (anti-miR-205-5p miRCURY LNA microRNA inhibitor, Quiagen), NS were dissociated to single-
cell suspensions, and 105 cells were transduced using TransIT-X2 Dynamic Delivery System (MirusBio) according to manufac-
turer’s instructions and cells were assessed 48 h after transfection. For transduction, NSwere dissociated to single-cell suspensions,
and 105 cells were transduced in standard medium with miRZIP Lentivector-based Anti-MicroRNAs (System Bioscience), or human
ERBB3 shRNA Lentiviral Particles (Locus ID 2065, OriGene Technologies) or FGFR3 shRNA Lentiviral Particles (Locus ID 2261, Or-
iGene Technologies), or human ERBB3 (pReceiver-Lv105-ERBB3) lentivector (GeneCopoeia) at a Multiplicity Of Infection (MOI) of 5.
Transduction efficiency was determined 72 h post-infection by fluorescent microscopy and quantitative Real Time PCR as above.
Empty vectors were used as controls.
Western blotting
Protein expression was analyzed in whole cell-lysates solubilized in boiling Laemmli buffer (for total protein extraction) or RIPA (for
single protein immunoprecipitation) or EB-extraction buffer (for protein co-immunoprecipitation), or in cytoplasmic and nuclear frac-
tions obtained as previously described (De Bacco et al., 2016). Cell-lysates were sonicated, quantified using BCA method (Pierce),
and 10 to 20 mg were resolved by SDS-PAGE in reducing conditions (BioRad) and blotted onto nitrocellulose membrane (BioRad).
After blocking, the following primary antibodies were used (see Key resources table for detail): anti-MET (DL21, Candiolo Cancer
Institute), anti-ERBB3, anti-EGFR, anti-ERBB4, anti-PDGFRA, anti-PDGFRB, anti-FGFR1, anti-FGFR2, anti-FGFR4, anti-MAP2,
anti-BCL2, anti-phospho-ERBB3 (Tyr1289, Tyr1222, Tyr1197), anti-c-KIT, anti-phospho-p44/42 MAPK, anti-phospho-AKT
(Ser473), anti-phospho-FRS2 (Tyr436), anti-phospho-mTOR, anti-phospho-RAPTOR, anti-RAPTOR, anti-phospho-S6, anti-S6,
anti-phospho-4EBP1, anti-GLUT1, anti-cleaved PARP and anti-caspase 3 (Cell Signaling Technology), anti-ERBB2 (Thermo Fisher),
anti-NTRK2 (R&D), anti-NEDD4 (Bethyl), anti-FGFR3 and anti-NRDP1 (NovusBio), anti-LDHB (abcam), anti-phospho-Tyr (Millipore).
b-actin and Calnexin (Cell Signaling Technology), TATA binding Protein (TBP) and vinculin (Sigma-Aldrich), and GAPDH (Abcam)
were used as protein loading control as indicated. For co-immunoprecipitation and ERBB3 phosphorylation, equal amounts of pro-
teins were immunoprecipitated using the following antibodies: mousemonoclonal anti-ERBB3 (Millipore), anti-ERBB2 (Trastuzumab,
Roche), anti-MET (DO24, Candiolo Cancer Institute), anti-EGFR, anti-PDGFRA, anti-PDGFRB, anti-KIT (Cell Signaling Technology),
anti-NTRK2 (R&D System), anti-FGFR3 (NovusBio), and analyzed by western blotting with anti-pan-phospho-Tyr antibodies (Milli-
pore), and the above antibodies. For multiple protein detection in immunoprecipitates, membranes were stripped using stripping
buffer solution (Thermo Fisher). After membrane incubation with HRP-conjugated secondary antibodies (Jackson Lab), enhanced
chemiluminescence (Biorad) was used for detection; blot images were acquired with the ChemiDoc TouchTM Imaging System (Bio-
rad) with Image Lab software. Results are representative of at least 2 independent experiments.
Flow-cytometric analysis
NS were manually dissociated and resuspended in PBS 1% BSA at a concentration of 2 3 106 cells/ml. For surface markers
detection, cells were incubated for 15 min at room temperature with the following antibodies (see Key resources table for de-
tails): anti-ERBB3-PE (clone REA508, Miltenyi Biotec GmbH); anti-ERBB3-APC (clone 1B4c3) and anti-ERBB2 (clone 5D3) (Bio-
legend); anti-ERBB4 (polyclonal anti-goat, R&D System); anti-EGFR (clone EGFR.1, BD Bioscience); anti-FGFR2 (clone 98725),
anti-FGFR3 (clone 136334) and anti-FGFR4 (clone 240929) (R&D System); anti-PDGFRA (clone 16A1) (Biolegend); anti-HGF
R/MET (clone 95106, R&D System); anti-NTRK2 (clone 72509, R&D System); anti-c-KIT (clone 104D2, Immunological Sciences).
DAPI (Roche) was used for dead cells exclusion. Analysis was performed on a CyAn ADP (Beckman Coulter) equipped with
488nM, 405nM and 642nM solid state lasers and data were processed using Summit 4.3 software (Beckman Coulter). When-
ever appropriate, the compensation matrices available with software, including the VisiComp scaling algorithm were applied in
order to avoid overcompensation errors. For each antibody, unstained cells, obtained from the same NS culture and treated as
stained cells, were used to determine background fluorescence and to set negative gates appropriately. In multicolor staining,
the Fluorescence Minus One methodology was applied in order to avoid interferences (Hulspas et al., 2009; Maecker & Trotter,
2006). EGFR family antibodies validation and gating strategy are shown in Figures S11A and S11B.
Flow-cytometric single cell imaging
Amnis ImageStream system were used to define co-localization of ERBB3 and FGFR3 in single cells obtained from ERBB3-high NS.
NS were mechanically dissociated and 1x107/ml cells were incubated for 30 min at room temperature with the following antibodies:
anti-ERBB3-PE (clone REA508, Miltenyi Biotec GmbH, 1:10) and anti-FGFR3-APC (clone 136334, R&D System, 1:5). Hoechst 33342e8 Cell Reports 36, 109455, July 27, 2021
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equipped with 488 nM, 405 nM and 642 nM solid state lasers, and analysis were performed by Amnis IDEAS 6.2 image analysis soft-
ware (Luminex).
Immunofluorescence analysis
Immunofluorescence analyses were performed either in NS or FFPE experimental tumor sections. Samples were fixed 10 min with
PFA 4%at 4C, permeabilizedwith Triton 0.2% for 10min, washed and saturatedwith PBS-TWINBSA 5% for 1 h. Primary antibodies
for anti-ERBB3 (Cell Signaling Technology) or anti-FGFR3 (NovusBio) (see Key resources table), were incubated for 1 h at room tem-
perature and then overnight at 4C. AlexaFluor conjugated anti-rabbit or anti-mouse secondary antibodies (1:1000, Thermo Fisher)
were incubated for 1 h. DAPI was used for nuclear counterstaining. Images were acquired using a LEICA SPEII confocal microscope
and are representative of at least three independent immunostainings.
Immunohistochemistry and Tunel assay
Analysis of parental tumor samples was performed on 3 mm section starting from Carnoy fixed, paraffin embedded samples. For
ERBB3 and ERBB2 immunostaining, heat induced epitope retrieval (HIER) was performed in PT Link pre-treatment module (Agilent)
using Target retrieval solution high pH (Dako), and sections were then incubated with anti-ERBB2 (Agilent) or anti-ERBB3 antibodies
(Sigma-Aldrich). For EGFR immunostaining with anti-EGFR (Thermo Fisher) no antigen retrieval was required. As secondary anti-
bodies, anti-rabbit Envision HRP-conjugated (Agilent) was used for ERBB3, while FLEX HRP-conjugated was used for ERBB2
and EGFR antibodies. Staining was detected using the diaminobenzidine (DAB Substrate Chromogen System, Agilent) and counter-
stained with hematoxylin. ERBB3, ERBB2 and EGFR expression was evaluated by B.P. andM.P., and was scored semiquantitatively
as 0, 1+ or 2+, based on the percentage of positive cells and staining intensity. Immunohistochemistry analysis on experimental
GBMs was performed on 2 mm FFPE sections collected on polarized slides. Haematoxylin-Eosin staining (H&E) was performed.
ERBB2 and EGFR detection was performed as described above with appropriate staining controls: EGFR amplified GBM
(#BT379) and ERBB2 amplified breast cancer PDX (kindly provided by Dr. Sassi and Prof. Trusolino) (Figure S11C). For ERBB3, phos-
pho-S6 and ki-67 immunostaining, sections underwent heat-induced antigen retrieval via microwaves; for LDHB pre-heat water bath
and citrate buffer were used. Sections were then incubated with primary antibody diluted in TBS 1% BSA overnight at 4C. The
following antibodies were used: anti-ERBB3 (Protein human Atlas), anti-phospho-S6 (Cell Signaling Technology), anti-LDHB (Abcam)
and anti-ki-67 (Agilent) (see Key resources table). Sections were then incubated with the appropriate secondary HRP-conjugated
antibodies and DAB (Dako).
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL assay, Promega) was used to measure apoptotic index in
experimental GBMs at the endpoint. FFPE tumors were sectioned according to manufacturer’s instruction. TUNEL-positive cells
were quantified by averaging the number of positive nuclei in six high-power fields (HPF, 400 3 magnification) per mouse (n = 3/
group), excluding necrotic areas.
Duolink proximity ligation assay
104 NS cells were fixed as above and the DuoLink proximity ligation assay (PLA) kit (Sigma-Aldrich) was used according to manu-
facturer’s instructions. Briefly, primary antibodies (for dilutions and details see Key resources table) were incubated overnight at
4C, then Duolink PLA probes detecting rabbit or mouse antibodies were incubated for 2 h. Secondary antibodies hybridized
when the two different PLA probes (anti-rabbit minus probe and anti-mouse plus probe) were bound to proteins closer than
40 nm. After ligation and amplification steps, the signal generated by fluorescently labeled oligonucleotides was detected by fluo-
rescence microscopy as a point-shaped signal. ERBB3-neg NS were used as specificity control, as well as cells stained with only
ERBB3 or FGFR3 antibodies. Images were acquired as described above.
Lactate release and pH measurement
NS were kept in standard medium at clonal dilution for 3 days, with or without MM121, and then culture supernatants were collected
and immediately analyzed. Lactate release was evaluated by Lactate-GloAssay and GloMax 96 Microplate Luminometer (Promega)
according tomanufacturer’s instructions. pHwasmeasured by a pHmeter (Basic 20, Crison), calibrated before each experiment with
standard medium supplied with serial dilutions of HCl or NaOH. Technical and biological replicates were performed (n R 3). Data
were reported as mean ± SEM of at least two independent experiments (n > 6).
Extracellular Acidification (ECAR) and Oxygen Consumption Rates (OCR)
Glycolytic Rate Assay and XF Cell Mito Stress were used for evaluating ECAR and OCR respectively with the Seahorse XFe96 instru-
ment (Agilent), according to manufacturer’s instructions. Cells were dissociated from exponentially growing NS kept in standard me-
dium and 1.2 3 104 cells/well were plated in XF96 microplates (Agilent) coated with Cultrex BME PathClear (Tema Ricerca) in
fresh standard medium for 24 h. The following day, medium was replaced with the Seahorse XF base medium supplemented with
1 mmol/L L-glutamine for ECAR or 10 mmol/L glucose, 2 mmol/L glutamine and 1 mmol/L pyruvate for OCR. For normalization,
at the end of the experiments, cells were fixed, stained with DAPI and counted using Cytation 3 Cell Imaging Reader (BioTek
Instrument).Cell Reports 36, 109455, July 27, 2021 e9
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103 NS cells/well were seeded in a 96-well plate at day 2 in a medium devoid of any growth factor for measuring the response to
growth factors, or in standard medium (EGF + bFGF) for experiments with ERBB3 or FGFR inhibitors, shRNA and miR-205. Growth
factors and/or MM121 or BGJ398 were added at day 0 and ATP production was measured by CellTiter-Glo (Promega) at the indi-
cated time points. For apoptosis, Annexin V incorporation was measured by RealTime-GloAnnexin V Apopt and Nec Assay (Prom-
ega) according to manufacturer’s instructions at the indicated time points. Assays were measured using a GloMax 96 Microplate
Luminometer (Promega). Data were reported as mean ± SEM of at least two independent experiments (n > 6).
Annexin V and caspase 3 activity evaluation by flow-cytometry
NS were kept in standard medium and MM121 for 24 h. To evaluate different apoptosis phases, eBioscience Annexin V Apoptosis
Detection Kit (Thermofisher) and DAPI (Roche) were used according tomanufacturer instructions. Apoptosis phases were defined as
follow: viable, annexin Vneg/DAPIneg cells; early apoptotic, annexin Vpos/DAPIneg; late apoptotic, annexin Vpos/DAPIpos; necrotic, an-
nexin Vneg/DAPIpos. For flow cytometric evaluation of activated caspase-3, NSwere permeabilized with FIX&PERMKit (Nordic-MU-
Bio) according to manufacturer’s instructions, and then were incubated with purified rabbit anti-active caspase-3 (BD Biosciences).
Reported values are the mean ± SEM of two independent experiments.
Cell cycle analysis
Cell cycle was analyzed as previously described (De Bacco et al., 2016). Briefly, 106 cells were fixed overnight with 70% ethanol,
stained with Propidium Iodide (PI, 50 mg/ml) in RNaseA (100 mg/ml) solution (DNAcon3 kit ConsulTS) for 3 hours at 4C, and analyzed
by flow-cytometry. Data are the mean ± SEM of at least two independent experiments.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data were expressed as mean ± standard error of the mean (SEM) of at least two independent experiments. Statistical comparisons
were performed using the parametric Student’s t test, one-way Analysis of Variance (ANOVA) and Pearson’s correlation, or the non-
parametricMann-Whitney test, 2-way ANOVA, and Kolmogorov-Smirnov test. Survival curveswere analyzed using the Kaplan-Meier
method with groups compared by respective median survival; the non-parametric Mantel-Cox and Wilcoxon tests were used for
calculating log-rank p values. A p-value < 0.05 was considered significant. All statistical tests were performed with Prism v8.0 soft-
ware (GraphPad). Statistical details of all experiments can be found in the figure legends, including exact number (n) of cell samples or
mice.e10 Cell Reports 36, 109455, July 27, 2021
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Figure S1. ERBB3 overexpression defines a subset of proneural GBMs with oligodendroglial 
features and dismal prognosis, related to Figure 1 
(A) ERBB3 expression measured by IHC in representative GBMs from the cohort that originated 
the 84-NS panel (n = 28). Red dots, patients matched with ERBB3-high NS. 
(B) Heatmap showing spontaneous clustering of primary GBMs (TCGA, n = 497) according to 
mRNA levels of the indicated genes. 
(C) Heatmap showing subtyping of the 84 NS-panel according to the classical (CL), proneural (PN) 
and mesenchymal (MES) classification system (Wang Q. et al., 2017).  
(D) Heatmap showing Nearest Template Prediction algorithm (NTP) subtyping of the 84 NS-panel 
according to the Type I and Type II classification system (Wang Z. et al., 2020). NS with FDR > 
0.05 were classified as non-Type I&II.  
(E) Gene set enrichment analysis of oligodendrocyte, astrocyte and neuron markers in ERBB3-high 
versus ERBB3-low/neg NS performed in the 84-NS panel microarray. In ERBB3-high NS 
oligodendrocyte markers are significantly enriched, while astrocyte markers are significantly 
anticorrelated. ES, enrichment score; FDR, false discovery rate.  
(F and G) Heatmaps showing mRNA levels (microarray) of the indicated genes in the 84 NS-panel 
(F) and in the TCGA GBM cohort (n = 497) (G). Pearson correlation coefficient (R) with ERBB3 
and relative p-values are reported. 
(H) Mutational profile (oncoprint) and O-6-methylguanine-DNA methyltransferase (MGMT) 
promoter methylation status of ERBB3-high NS. Colored rectangles indicate copy number 
variations, colored dots sequence alterations (see legend). p.TERT, TERT promoter. 
(I) ERBB3 gene copy number measured by qPCR in 84 NS-panel gDNA, showing no significant 
variation in any NS subgroup. CN, copy number. Mean ± SEM (n = 20 ERBB3-neg, n = 12 
ERBB3-low, n = 7 ERBB3-high). 
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(J and K) Frequency of alterations (mutations and/or copy number variations) of the indicated GBM 
driver genes in ERBB3-high and ERBB3-low/neg cases (according to ERBB3 mRNA levels), in the 
84-NS panel (J) and TCGA GBM cohort (K). Overall alteration frequency is also shown. 
Preferential association or anticorrelation between genetic alterations and ERBB3 expression was 
evaluated by Fisher’s exact test. Significant p values in the TCGA GBM cohort and the 
corresponding p values in the 84 NS-panel are reported. ERBB3, EGFR: amplification and 
mutation; CDKN2A: homozygous deletion; PDGFRA, CDK4, CDK6, MDM2, MDM4: 
amplification; PTEN: homozygous deletion and mutation; TP53, PIK3CA, IDH1: mutation; MGMT: 
promoter methylation. 
(L) Tumor take and ki67 index (positive cells/nuclei, mean ± SEM, n = 5) in experimental GBMs 
obtained by orthotopic transplantation of proneural ERBB3-high or –low/neg NS. The 
mesenchymal ERBB3-low NS BT302 used for further in vivo experiments is also shown. ERBB3-
high NS are significantly more aggressive than ERBB3-low/neg NS (unpaired t test with Welch’s 
correction, p = 0.0027).  
(M) ki67 staining in representative tumors obtained as in (L) with an ERBB3-high (BT308) or 
ERBB3-neg NS (BT463). Scale bar, 50µm. 








Figure S2. ERBB3 expression in the 84-NS panel, related to Figure 1. 
(A) ERBB3 mRNA expression levels (qPCR) shown as log2 ratio (L2R) in the 84 NS-panel. Dotted 
line, threshold (L2R = 2.5) to discriminate ERBB3-high NS (red columns) from ERBB3-low (0 < 
L2R ≤ 2.5) and ERBB3-neg (L2R < 0). Expression values for each NS are reported in Table S1. 
(B) ERBB3 expression in representative ERBB3-high, -low and -neg NS evaluated at mRNA (L2R, 
qPCR) and protein level (WB, western blot of total, cytoplasmic and nuclear extracts; flow-
cytometry; and IF, immunofluorescence). Percentages of ERBB3 positive cells and mean 
fluorescence intensity (MFI) measured by flow-cytometry are reported. TATA Binding Protein 
(TBP), loading control; DAPI, nuclear staining. Scale bar, 25 µm. IF higher magnification is shown 
in (E). 
(C and D) ERBB3 protein expression in a representative ERBB3-high NS (BT308) compared with 
the indicated cancer cell lines, measured by flow-cytometry (C) and western blot (D). actin, loading 
control.  
(E) ERBB3 localization evaluated by IF in ERBB3-high (BT308) and ERBB3-low NS (BT302). In 
magnified micrographs (right), arrows indicate nuclear clusters. Scale bar, 12.5 µm. 
(F) ERBB3 mRNA expression (qPCR) in clones derived from subcloning of an ERBB3-high NS 
(BT308). Results are shown as fold versus parental BT308 expression (mean ± SEM, n = 3). BT463 
(ERBB3-neg NS), negative control. 
(G) Western blot showing similar levels of ERBB3 protein in BT308 and its subclones. BT463 
(ERBB3-neg NS), negative control; GAPDH, loading control.  
(H) Western blot showing ERBB3 expression in NS and their progeny grown in 
pseudodifferentiating conditions (diff) for 4 days. MAP2 is used as differentiation marker, MET as 
positive control of RTK downregulation during differentiation; actin, loading control.  







Figure S3. ERBB3 overexpression is sustained by inactivation of the oncosuppressor miR-205, 
related to Figure 2. 
(A) Possible mechanism(s) responsible for ERBB3 post-transcriptional downregulation: protein 
targeting to ubiquitination (Ub) by NEDD4 or NRDP1, or mRNA degradation by miR-205.  
(B) Western blot showing lack of inverse correlation between ERBB3 and NEDD4 or NRDP1 
expression in representative ERBB3-high and –low/neg NS. GAPDH, loading control.  
(C) miR-205 and ERBB3 expression (qPCR) in ERBB3-high NS (BT308 and BT209) transduced 
with miR-205. Mean ± SEM, n = 3. 
(D-F) lnc-RNA SNHG5 expression (qPCR) in representative ERBB3-high and –low/neg NS (D), 
parental (E) and experimental (F) GBMs. L2R, log2ratio. Mean ± SEM, n = 3. 
(G) Seed binding regions located in the ERBB3 3’UTR (ENST00000267101.3). Highly conserved 
miRNAs displaying high complementary score (≥ 90%) were shown (TargetScanHuman).  
(H-I) miR-125a/b, -148, -152 and -22 expression in representative ERBB3-high (n = 5) and –
low/neg (n = 6) NS (H) and in the TCGA GBM cohort (n = 339) subdivided according to ERBB3 
expression (I). No significant correlation between ERBB3 expression and any of these miRNAs has 
been observed (one-way ANOVA, in all cases p > 0.5). Mean ± SEM. 
(J) Alternative mechanisms (promoter methylation or neutralization by lnc-RNA SNHG5) for miR-













Figure S4. ERBB3 is overexpressed in the absence of other EGFR family members, related to 
Figure 3. 
(A-B) Heatmap showing matrix correlation of ERBB3 with the other EGFR family members in the 
84 NS-panel (n = 84) (A) and in the TCGA GBM cohort (n = 497) (B). Pearson coefficients (R) and 
correlation plots are shown (* p < 0.05). 
(C) Flow-cytometry showing expression of EGFR family members in representative ERBB3-high 
and –low NS. Mean fluorescence intensity (MFI) and % of positive cells are reported. 
(D) Table showing the cumulative score (resulting from staining intensity + percentage of positive 
cells) after ERBB3 or ERBB2 IHC of GBMs from the TCGA cohort evaluated by the Human 
Protein Atlas. All available cases co-stained for ERBB3 and ERBB2 were included. No GBM 
displays ERBB3-ERBB2 co-staining.  
(E) Representative IHC showing ERBB3, ERBB2, EGFR or ERBB4 staining of the same GBM 
tissues from the TCGA cohort performed by the Human Protein Atlas. Inset, higher magnification. 
Image credit: Human Protein Atlas. 
(F) Stimulation of ERBB3-high NS, kept in the absence of any growth factor for 48 h, with NRG1 
(left) or EGF (right) for 30’, followed by immunoprecipitation and western blot with the indicated 
antibodies, showing no ERBB3 phosphorylation or coprecipitation with ERBB2 or EGFR. Cancer 
cell lines A549 and A375 were used as positive controls. ctrl, PBS treated cells; pTyr, anti-pan-
phosphotyrosine. 
(G) Cell viability in response to the indicated growth factors measured 4 days after treatment in 
representative ERBB3-high (BT308 and BT209) or –low NS (BT373). Dotted line, fold-increase 
versus cells kept in the absence of growth factors (no GF) = 1. Mean ± SEM, n = 5. 
(H) Western blot showing lack of ERBB3 phosphorylation on Tyr1289 at the indicated time points 
after treatment with the EGFR ligand EGF in representative ERBB3-high/EGFR-neg NS (BT308). 
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Activation of downstream signaling transducers AKT and MAPK is also shown. ERBB3-







Figure S5. Overexpressed ERBB3 is activated by bFGF via FGFR3, related to Figure 3. 
(A) Cell viability in representative ERBB3-high (BT308 and BT209) or –low NS (BT373) 
measured 5 days after treatment with or without pan-FGFR inhibitor BGJ398 in the presence of 
bFGF. Mock, PBS-treated cells (* p < 0.001, paired t test). Mean ± SEM, n = 6. 
(B) Western blot showing phosphorylation (p) of ERBB3 on Tyr1289 and Tyr1197, AKT and 
MAPK in ERBB3-high NS BT308 kept in the absence of any growth factor for 48 h and treated 
with bFGF for the indicated time-points. FRS2 phosphorylation was shown as surrogate marker of 
FGFR activation. ctrl, PBS treated cells; vinculin, loading control. The same vinculin immunoblot 
is shown in Figure 4B as part of the same experiment. 
(C) Immunoprecipitation with anti-ERBB3 antibodies and western blot showing ERBB3 
phosphorylation on Tyr1289 and ERBB3 total protein in ERBB3-high NS (left, BT314; right, 
BT308) pre-treated with or without the pan-FGFR inhibitor BGJ398 (BGJ) and supplied with 
bFGF. NS were kept in the absence of any growth factors for 48 h prior to treatment. Mock, PBS 
treated cells.  
(D) Flow-cytometric quantification of the ERBB3 relative amount exposed at the cell surface (%) at 
different time points after treatment with MM121 in ERBB3-high NS (BT308). Mean ± SEM, n = 
3. 
(E) Western blot showing ERBB3 phosphorylation on Tyr1289 and total protein levels after 
treatment with MM121 in ERBB3-high NS (BT308 and BT314) kept in standard medium (EGF + 
bFGF). Mock, PBS-treated cells; calnexin, loading control.  
(F) Correlation plots between ERBB3 and FGFR1, FGFR2, FGFR3, or FGFR4 mRNA expression 
(L2R) in the 84-NS panel. Pearson correlation coefficients (R) and p-values are reported. Red dots, 
ERBB3-high NS. 




(H) Western blot showing FGFR family members in representative ERBB3-low (BT373 and 
BT302) and ERBB3-high NS (BT308 and BT209). Vinculin, loading control. 
(I) Flow-cytometry showing FGFR2, FGFR3 and FGFR4 expression in representative ERBB3-high 
NS (BT209, BT308 and BT314). Mean fluorescence intensity (MFI) and % of positive cells are 
reported. 
(J) Cell viability of ERBB3-high BT308, kept in the absence of any growth factor for 48 h, 
transduced with a specific FGFR3 shRNA (shFGFR3) and supplied with bFGF for 2 days. a.u., 
arbitrary units (* p < 0.001, shFGFR3 versus shCTRL paired t test). Mean ± SEM, n = 6. 
(K) Co-localization of ERBB3 and FGFR3 measured by Amnis ImageStream in single cells from 
representative ERBB3-high-NS (BT209). Single and merged fluorescent antibody signals are 
shown. BF, bright field. 
(L) Proximity ligation assay (PLA) showing ERBB3-FGFR3 interaction in representative ERBB3-
high NS (BT314). ERBB3-neg NS (BT463) is used as negative control. DAPI, nuclear staining. 
Scale bar, 75 µm. 
(M) Flow-cytometry showing FGFR2, FGFR3 and FGFR4 expression in representative ERBB3-
low (BT302 and BT373) and –neg NS (BT463). Mean fluorescence intensity (MFI) and % of 
positive cells are reported. 
(N) Cell viability in representative ERBB3-low (BT373) and –neg (BT463) NS measured at the 
indicated time points in the presence of EGF or bFGF or both (EGF + bFGF) (* p < 0.001, paired t 







Figure S6. Lack of ERBB3 activation by MET, PDGFRs, KIT and NTRK2, related to Figure 
3. 
(A and B) Heatmap showing matrix correlation of ERBB3 with the indicated RTKs in the 84 NS-
panel (n = 84) (A) and in the TCGA GBM cohort (n = 497) (B). Pearson coefficients (R) and 
correlation plots are reported (* p < 0.05). 
(C) Flow-cytometry showing ERBB3 co-expression with different RTKs in representative ERBB3-
high NS (BT209 and BT308). 
(D) Stimulation of ERBB3-high NS, kept in the absence of any growth factor for 48 h, with 
hepatocyte growth factor (HGF, MET ligand), or platelet derived growth factor BB (PDGFBB, 
PDGFRA and –B ligand), or stem cell factor 1 (SCF1, KIT ligand) or brain derived neurotrophic 
factor (BDNF, NTRK2 ligand) for 30’, followed by immunoprecipitation and western blot with the 
indicated antibodies, showing no ERBB3 phosphorylation or coprecipitation with any of the above 
receptors. Cancer cell lines A549, A375 and HeLa were used as positive controls for receptor 






Figure S7. In ERBB3 overexpressing NS, bFGF sustains the PI3-K/AKT/mTOR pathway and 
metabolic hyperactivation, related to Figure 4. 
(A) Western blot showing phosphorylation (p) of mTOR pathway effectors in ERBB3-high NS 
(BT209) kept in the absence of any growth factor for 48 h and treated with bFGF for the indicated 
time-points. Ctrl, PBS-treated cells; vinculin, loading control. The same vinculin immunoblot is 
shown in Figure 3G as part of the same experiment. 
(B) Expression of mTOR target genes SREBF2, HIF1A and TFAM in ERBB3-high (BT205 and 
BT209) and ERBB3-low NS (BT302 and BT373) kept in the absence of any growth factor for 48 h 
and treated with bFGF for 24 h. Mean ± SEM, n = 3. 
(C) Correlation plots between ERBB3 and LDHB mRNA expression (L2R) in the TCGA GBM 
cohort (n = 497). Pearson correlation coefficient (R) and p-value are reported.  
(D and E) Gene set enrichment analysis of ERBB3-high versus ERBB3-low/neg cases performed in 
the 84 NS-panel (n = 84) (D) and in the TCGA GBM cohort (n = 497) (E), showing that genes 
upregulated in low pH conditions are prominently enriched in ERBB3-high NS and GBMs. 
(F) Oxygen Consumption Rate (OCR) measured by Seahorse mitochondrial stress assay of 
representative ERBB3-high (BT308) and ERBB3-low/neg NS (BT452 and BT373) assessed in 
basal conditions (standard medium, EGF + bFGF) (mean ± SEM, n = 4; * p < 0.001, two-way 
ANOVA). ROT/AA: rotenone/antimycin A. 
(G) OCR measured as in (F) in representative ERBB3-high NS (BT209 and BT308) assessed 24 h 
after treatment with or without BGJ398 in standard medium (EGF + bFGF) (mean ± SEM, n = 6; 
paired t test mock versus BGJ treated NS, p < 0.001). Mock, PBS-treated cells. 
(H) Extracellular Acidification Rate (ECAR) in representative ERBB3-high NS (BT209 and 
BT308) and ERBB3-low/neg NS (BT373) assessed as in (G) (mean ± SEM, n = 5, paired t test 




(I) Representative XF PhenoGram obtained by plotting basal OCR versus basal ECAR values 
obtained in the experiments shown in (H). 








Figure S8. ERBB3 overexpression is required for the PI3-K/AKT/mTOR pathway and cell 
metabolism upregulation, related to Figure 5. 
(A) Expression of the mTOR target genes SREBF2, HIF1A and TFAM 24 h after treatment with or 
without MM121 in ERBB3-high NS (BT205 and BT209) kept in standard medium (EGF + bFGF). 
Mock, PBS-treated cells. Mean ± SEM, n = 3. 
(B) Extracellular Acidification Rate (ECAR) measured by Seahorse glycolytic rate assay in 
representative ERBB3-high (BT209) and ERBB3-low NS (BT463), assessed 24 h after treatment 
with or without MM121 in standard medium (EGF + bFGF) (mean ± SEM, n = 4; two-way 
ANOVA, p < 0.001). Mock, PBS-treated cells; ROT/AA: rotenone/antimycin A; 2-DG: 2-Deoxy-d-
glucose. 
(C) Oxygen Consumption Rate (OCR) measured by Seahorse mitochondrial stress assay in 
representative ERBB3-high (BT308) and ERBB3-low NS (BT463), assessed 24 h after treatment 
with or without MM121 in standard medium (EGF + bFGF) (mean ± SEM, n = 4; two-way 
ANOVA, p < 0.001). Mock, PBS-treated cells. 
(D) Western blot showing ERBB3 and LDHB expression in representative ERBB3-high NS 
(BT308 and BT209) transduced with a specific ERBB3 shRNA (shERBB3; shCTRL, mock-
transduced NS) and kept in standard medium (EGF + bFGF). calnexin: loading control. 
(E) Lactate release in culture media from NS treated as in (D) (* p < 0.005, paired t test). a.u., 
arbitrary units. Mean ± SEM, n = 3. 








Figure S9. Selective ERBB3 inhibition induces ERBB3-high NS apoptosis, related to Figure 6. 
(A) Cell viability measured in ERBB3-high (BT308) or -low NS (BT373) at the indicated time 
points after treatment with or without MM121 in standard medium (EGF + bFGF). Mock, PBS-
treated cells. (* p < 0.05, paired t test). Mean ± SEM, n = 6. 
(B) Cell distribution in different cell cycle phases evaluated by flow-cytometry in ERBB3-high 
(BT308) or ERBB3-low NS (BT373) 24 h after treatment with or without MM121 in standard 
medium (EGF + bFGF). Mock, PBS-treated cells. 
(C) Percentage of cells in the subG0 phase evaluated as in (B) in representative ERBB3-high, -low 
and –neg NS. Mock, PBS-treated cells. 
(D) Induction of pro-apoptotic genes in ERBB3-low (BT373 and BT302) and ERBB3-high NS 
(BT209, BT308 and BT205) 24 h after treatment with MM121 in standard medium (EGF + bFGF). 
Data (qPCR) are expressed as fold versus PBS-treated cells, mean ± SEM, n = 3.  
(E) Micrographs of ERBB3-high (BT308 and BT209) and ERBB3-low NS (BT373) 96 h after miR-
205 transduction. Mock, non-transduced cells. Scale bar, 50µm. 
(F) Cell viability measured in ERBB3-high NS (BT308 and BT314) 96 h after miR-205 
transduction (* p < 0.05, paired t test). Mock, non-transduced cells. Mean ± SEM, n = 6. 
(G and H) Cell apoptosis measured as Annexin V/DAPI incorporation (G) and Caspase-3 activation 







Figure S10. ERBB3 antibodies inhibit ERBB3-high experimental GBMs, related to Figure 7.  
(A) Representative ERBB3 IHC staining in tumors generated by subcutaneous transplant of 
ERBB3-high NS (BT209). ERBB3-high tumors displayed ERBB3 nuclear staining (arrows). Scale 
bar, 100 µm. 
(B) Representative ki67 and TUNEL stainings of tumors generated as in (A), treated with or 
without MM121, and analyzed at the experimental end point (left). Quantification of the percentage 
of ki67 and TUNEL positive cells (n = 10 HPF/condition) (ki67: * p = 0.029; TUNEL: * p = 0.008; 
Kolmogorov-Smirnov test) (right). Scale bar, 100 µm (ki67) and 25µm (TUNEL). 
(C) Representative ki67 and TUNEL stainings of tumors generated by subcutaneous transplant of 
ERBB3-low NS (BT302) treated with or without MM121, and analyzed at the experimental end 
point (left). Quantification of the percentage of ki67 and TUNEL positive cells (n = 10 
HPF/condition) (right). Scale bar, 100 µm (ki67) and 25 µm (TUNEL). 
(D) Representative IHC staining of ERBB3, phospho-S6 (pS6) and LDHB on the same tumors as in 







Figure S11. Antibody validation, related to STAR Methods.  
(A) Validation of antibodies used for measuring expression of EGFR family receptors in NS by 
flow-cytometry. For each antibody, the indicated negative, low- and high-expressing conventional 
cell lines were used. The percentage of positive cells and the mean fluorescence intensity (MFI) 
were calculated by comparing stained (red line) versus unstained (grey line) cells in each sample.  
(B) The flow-cytometric gating strategy is established for each sample in unstained negative control 
cells to exclude debris (R1), doublet cells (R2) and dead cells (R3), by analysis of physical 
parameters (SS, side scatter; FS, forward scatter; DAPI staining). 
(C) Validation of ERBB2 and EGFR antibodies used in IHC staining. Human and experimental 
tumor tissues overexpressing ERBB2 (HER2
+
 human breast cancer metastasis, parental tumor and 
mouse xenograft) or EGFR (EGFR
amp
 GBM, parental and generated by NS (BT379) 
transplantation). Scale bar, 100 µm. 
(D) Validation of ERBB4 antibodies used in western blot analysis. Breast cancer cell line T47D was 
used as positive control and compared to representative ERBB3-high NS (BT308, BT209 and 





























BT209 4.89 PN II 
BT454 4.09 PN II 
BT337 3.69 PN II 
BT358 3.62 MES II 
BT308 3.61 PN II 
BT205 3.10 PN II 












BT373 2.49 PN II 
BT430 2.28 PN non I-II 
BT407 2.13 PN non I-II 
BT326 1.85 PN non I-II 
BT138 1.59 CL non I-II 
BT443 1.49 PN non I-II 
BT284 1.41 PN I 
BT201 1.35 PN non I-II 
BT419 1.24 CL I 
BT414 1.16 CL non I-II 
BT302 1.12 MES non I-II 
BT434 1.03 CL I 
BT446 0.85 CL I 
BT334 0.82 CL non I-II 
BT422 0.48 CL non I-II 
BT283 0.47 PN I 
BT428 0.46 CL I 
BT437 0.44 MES I 
BT418 0.43 PN non I-II 
BT266 0.38 PN non I-II 
BT500 0.37 CL I 
BT235 0.36 PN I 
BT299 0.27 MES non I-II 
BT462 0.19 PN I 
BT150 0.15 PN I 
BT333 0.14 PN non I-II 
BT294 0.14 CL I 
BT245 0.09 PN non I-II 
BT442 0.04 CL I 



























BT483 -0.05 CL I 
BT398 -0.06 MES I 
BT470 -0.07 CL non I-II 
BT517 -0.14 CL non I-II 
BT404 -0.15 MES non I-II 
BT159 -0.23 PN I 
BT423 -0.25 CL I 
BT275 -0.26 PN non I-II 
BT273 -0.37 PN non I-II 
BT513 -0.38 MES II 
BT453 -0.42 CL I 
BT479 -0.62 MES non I-II 
BT408 -0.63 CL I 
BT451 -0.69 CL I 
BT261 -0.75 CL I 
BT371 -0.87 MES II 
BT297 -0.88 CL I 
BT449 -1.04 MES non I-II 
BT249 -1.05 PN I 
BT328 -1.13 MES non I-II 
BT379 -1.20 CL non I-II 
BT413 -1.24 CL I 
BT468 -1.28 CL I 
BT332 -1.37 CL I 
BT487 -1.38 MES non I-II 
BT246 -1.41 CL I 
BT279 -1.43 PN non I-II 
BT202 -1.48 CL non I-II 
BT421 -1.52 PN II 
BT490 -1.54 CL non I-II 
BT330 -1.57 MES II 
BT232 -1.60 MES non I-II 
BT274 -1.63 PN non I-II 
BT445 -1.67 CL I 
BT493 -1.70 CL I 
BT155 -1.71 CL non I-II 
BT287 -1.73 MES II 
BT452 -1.74 MES non I-II 
BT322 -1.75 MES non I-II 
BT219 -1.78 MES II 
BT206 -1.81 PN non I-II 
BT480 -1.82 MES non I-II 
BT417 -1.83 CL I 
BT157 -1.84 MES II 
BT467 -1.86 MES II 
BT456 -1.92 MES II 
BT463 -1.93 PN non I-II 
 
1
Based on Wang Q. et al., 2017; CL, classical; MES, mesenchymal; PN, proneural;  
2




Table S2, related to Figure 1. Clinical data of patients that originated the 84-NS panel (all 
untreated primary glioblastomas, WHO grade IV gliomas)  
patient 
code 





BT138 F 37 F-T left 2 6 
BT150 M 59 P left 4 10 
BT155 F 45 F-T right 9 13 
BT157 M 53 T left n.a. 9 
BT159 M 52 F right n.a. 1 
BT201 M 61 P right 14 20 
BT202 M 69 T-P right n.a. 4 
BT205 M 73 L right n.a. 2 
BT206 M 67 F left n.a. 4.5 
BT209 M 55 T-P left 3.5 4.5 
BT219 M 54 T left n.a. 5 
BT232 M 49 T-P-O left n.a. 7.5 
BT235 M 68 F-T right n.a. 24.5 
BT245 F 53 T left 43 46 
BT246 M 61 F left 3 4.5 
BT249 M 63 T left n.a. n.a. 
BT261 M 63 T-P right n.a. 3 
BT266 M 7 DIPG n.a. 10 




BT274 M 48 T right 9 18 
BT275 F 66 P right n.a. 14 
BT279 F 58 P left n.a. 15 
BT283 F 44 P right 9 9.5 
BT284 M 74 O left 7 23.5 
BT287 M 70 F-T left 14 16 
BT294 M 54 O-P right 18 28.5 
BT297 M 53 T left n.a. 14 
BT299 M 48 T-P-O left n.a. 6.5 
BT302 F 17 F right n.a. n.a. 
BT308 M 76 T left n.a. 3 
BT314 M 67 T right n.a. 18 
BT322 M 66 F left 3.5 11.5 
BT326 M 27 F left 6 6.5 
BT328 M 54 F-P left n.a. 6 
BT330 M 58 F right n.a. 35.5 
BT332 M 74 O-P left n.a. 9 
BT333 F 37 T left n.a. 7 
BT334 M 63 F-T right n.a. 9 
BT337 M 63 T-P-F left 9.5 17.5 
BT358 F 62 F right n.a. 20 
BT371 F 46 F left 5 14.5 
BT373 M 62 F right 9 22 
BT379 M 72 F-P right n.a. 3 
BT398 M 48 Thm left 4 8 
BT404 M 57 F left 3.5 9.5 
BT407 M 55 T-F left n.a. 11 
BT408 F 61 P left 13 24 
BT413 F 71 T left n.a. 8.5 
BT414 F 65 O-P left n.a. 3 
BT415 M 47 P right 14 18.5 










BT418 F 67 P left 29 33 
BT419 M 64 P-T DX  n.a. 2 
BT421 M 65 T right n.a. 15 
BT422 M 68 F left 7.5 11 
BT423 F 39 F right 21 n.a. 
BT428 M 64 O-P right 34 n.a. 
BT430 F 70 T left 4 6 
BT434 M 74 F left n.a. 5 
BT437 M 48 T left 10 12 
BT442 F 58 T right 9 16 
BT443 M 65 T left 5.5 18 
BT445 M 60 I right 9 25 
BT446 M 45 O-P left n.a. n.a. 
BT449 M 68 T-O right 4.5 9 
BT451 F 37 F left n.a. 5 
BT452 F 65 T right n.a. 0 
BT453 M 58 T right 33 22.5 
BT454 M 75 P left n.a. 5 
BT456 M 60 T left 7.5 20 
BT462 M 70 F right 4 6.5 
BT463 M 69 T-P left 4.5 11 
BT467 M 57 F left n.a. 10.5 
BT468 M 63 P-T SIN 11 14.5 
BT470 M 41 F-P left n.a. 13 
BT479 M 52 O-P right n.a. 10 
BT480 F 68 F right 4 10 
BT483 M 36 F-T right 8 13 
BT487 M 70 T right 9 15 
BT490 F 73 T left 11 24 
BT493 M 43 F left 26 n.a. 
BT500 F 64 P left n.a. 20 
BT513 M 57 T left 4 9.5 
BT517 M 47 F left 7 13 
 
RED: ERBB3-high patients matched with ERBB3-high NS. All other patients are matched with ERBB3-low or –neg NS. 
PFS, progression Free Survival; OS, overall survival; F, frontal; P, parietal; T, temporal; O, occipital; L, lenticular; I, 
insular; Thm, thalamic. n.a., not available. 
